RAND CAPITAL CORP Form 10-Q November 07, 2018 Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from ______ to _____

Commission File Number: 814-00235

Rand Capital Corporation

(Exact Name of Registrant as specified in its Charter)

New York (State or Other Jurisdiction of Incorporation or Organization) 16-0961359 (IRS Employer Identification No.)

2200 Rand Building, Buffalo, NY (Address of Principal executive offices)

14203 (Zip Code)

(716) 853-0802

(Registrant s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer

Non-accelerated filer Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

As of November 5, 2018, there were 6,321,988 shares of the registrant s common stock outstanding.

RAND CAPITAL CORPORATION

TABLE OF CONTENTS FOR FORM 10-Q

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements and Supplementary Data	1
	Consolidated Statements of Financial Position as of September 30, 2018 (Unaudited) and December 31, 2017	1
	Consolidated Statements of Operations for the Three Months and Nine Months Ended September 30, 2018 and 2017 (Unaudited)	2
	Consolidated Statements of Changes in Net Assets for the Three Months and Nine Months Ended September 30, 2018 and 2017 (Unaudited)	3
	Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and 2017 (Unaudited)	4
	Consolidated Schedule of Portfolio Investments as of September 30, 2018 (Unaudited)	5
	Consolidated Schedule of Portfolio Investments as of December 31, 2017	13
	Notes to the Consolidated Financial Statements (Unaudited)	21
Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations	33
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	42
Item 4.	Controls and Procedures	42
	PART II. OTHER INFORMATION	
Item 1.	<u>Legal Proceedings</u>	43
Item 1A.	Risk Factors	43
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	43
Item 3.	<u>Defaults upon Senior Securities</u>	43
Item 4.	Mine Safety Disclosures	43
Item 5.	Other Information	43
Item 6.	<u>Exhibits</u>	44

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements and Supplementary Data
RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

ASSETS	September 30, 2018 (Unaudited)		D	ecember 31, 2017
Investments at fair value:				
Control investments (cost of \$99,500)	\$	99,500	\$	99,500
Affiliate investments (cost of \$20,413,709 and \$20,871,129, respectively)	Ψ	16,728,607	Ψ	17,016,795
Non Control/Non-Affiliate investments (cost of \$16,796,433 and \$15,718,690,		10,720,007		17,010,793
respectively)		15,344,150		15,167,767
respectively)		13,344,130		13,107,707
Total investments, at fair value (cost of \$37,309,642 and \$36,689,319,				
respectively)		32,172,257		32,284,062
Cash and cash equivalents		4,404,574		6,262,039
Interest receivable (net of allowance: \$211,342 at 9/30/18; \$161,000 at 12/31/17)		147,934		231,048
Deferred tax asset		772,275		551,863
Prepaid income taxes		1,122,826		762,047
Other assets		38,360		42,854
Other assets		30,300		42,034
Total assets	\$	38,658,226	\$	40,133,913
LIABILITIES AND STOCKHOLDERS EQUITY (NET ASSETS)				
Liabilities:				
Debentures guaranteed by the SBA (net of debt issuance costs)	\$	7,875,723	\$	7,855,173
Profit sharing and bonus payable		, ,		144,000
Accounts payable and accrued expenses		120,886		178,348
Deferred revenue		73,941		37,707
		- 7.		,
Total liabilities		8,070,550		8,215,228
Commitments and contingencies (See Note 5)		, ,		, ,
Stockholders equity (net assets):				
Common stock, \$.10 par; shares authorized 10,000,000; shares issued 6,863,034;				
shares outstanding of 6,321,988		686,304		686,304
Capital in excess of par value		10,581,789		10,581,789
Accumulated net investment loss		(1,643,744)		(1,597,146)
Undistributed net realized gain on investments		26,496,804		27,215,738
Net unrealized depreciation on investments		(4,064,372)		(3,498,895)
Treasury stock, at cost: 541,046 shares		(1,469,105)		(1,469,105)
		. , , ,		

Total stockholders equity (net assets) (per share \$4.84 at 9/30/18; \$5.05 at 12/31/17)

30,587,676

31,918,685

Total liabilities and stockholders equity (net assets)

\$ 38,658,226

\$ 40,133,913

See accompanying notes

1

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three months ended September 30, 2018		months mo ended en September 30, Septer		hs Nine ned ender 30, Septem		ne months ended tember 30, 2017
Investment income:							
Interest from portfolio companies:							
Affiliate investments	\$	192,758	\$	142,247	\$	515,784	\$ 416,247
Non-Control/Non-Affiliate investments		257,531		167,675		547,553	417,406
Total interest from portfolio companies		450,289		309,922		1,063,337	833,653
Interest from other investments:		ŕ		·			·
Non-Control/Non-Affiliate investments		7,872		6,348		20,717	24,182
		,		,		,	,
Total interest from other investments		7,872		6,348		20,717	24,182
Dividend and other investment income:		ŕ					
Affiliate investments		48,856		74,408		175,905	189,805
Non-Control/Non-Affiliate investments				2,405		6,058	7,598
Total dividend and other investment income		48,856		76,813		181,963	197,403
Fee income:							
Affiliate investments		4,042		2,166		11,625	6,250
Non-Control/Non-Affiliate investments		151,243		1,770		160,987	13,307
Total fee income		155,285		3,936		172,612	19,557
Total investment income		662,302		397,019		1,438,629	1,074,795
Expenses:							
Salaries		169,875		165,413		509,624	496,239
Employee benefits		39,845		38,454		148,841	138,523
Directors fees		28,624		36,374		92,123	107,623
Professional fees		81,745		48,433		220,773	310,628
Stockholders and office operating		47,839		45,355		176,877	193,290
Insurance		8,700		8,058		27,588	25,618
Corporate development		15,028		16,621		41,470	49,938
Other operating		4,875		2,772		9,990	8,055
		396,531		361,480		1,227,286	1,329,914
Interest on SBA obligations		77,568		77,568		232,406	232,706

Edgar Filing: RAND CAPITAL CORP - Form 10-Q

Bad debt (recovery) expense		(26,299)				50,342		
Bad debt (recovery) expense		(20,299)				30,342		
Total expenses		447,800		439,048		1,510,034		1,562,620
Net investment gain (loss) before income								
taxes		214,502		(42,029)		(71,405)		(487,825)
Income tax expense (benefit)		50,003		(17,050)		(24,807)		(188,961)
Net investment gain (loss)		164,499		(24,979)		(46,598)		(298,864)
Net realized loss on sales and dispositions of investments:								
Affiliate investments		(1,125,673)				(1,125,673)		
Net realized loss before income tax benefit		(1,125,673)				(1,125,673)		
Income tax benefit		406,739				406,739		
Net realized loss on investments		(718,934)				(718,934)		
Change in unrealized depreciation on investments:		, , ,				, , ,		
Affiliate investments		725,673				169,232		(665,675)
Non-Control/Non-Affiliate investments		(249,871)		111,000		(901,360)		(322,308)
Tion condon ton rimide investments		(21),071)		111,000		(501,500)		(322,300)
Change in unrealized depreciation before								
income tax expense (benefit)		475,802		111,000		(732,128)		(987,983)
Deferred income tax expense (benefit)		100,669		28,090		(166,651)		(349,960)
Net change in unrealized depreciation on								
investments		375,133		82,910		(565,477)		(638,023)
Net realized and unrealized (loss) gain on								
investments		(343,801)		82,910		(1,284,411)		(638,023)
Net (decrease) increase in net assets from								
operations	(\$	179,302)	\$	57,931	(\$	1,331,009)	(\$	936,887)
Weighted average shares outstanding		6,321,988		6,321,988		6,321,988		6,321,988
Basic and diluted net (decrease) increase in								
net assets from operations per share	(\$ See a	0.03) accompanying	\$ note	0.01	(\$	0.21)	(\$	0.15)

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS

(Unaudited)

	Se	Three months ended ptember 30, 2018	Se	Three months ended ptember 30, 2017	- '	ine months ended ptember 30, 2018	- '	ine months ended ptember 30, 2017
Net assets at beginning of period	\$	30,766,978	\$	31,634,545	\$	31,918,685	\$	32,629,363
Net investment gain (loss)		164,499		(24,979)		(46,598)		(298,864)
Net realized loss on investment		(718,934)				(718,934)		
Net change in unrealized depreciation on investments		375,133		82,910		(565,477)		(638,023)
Net (decrease) increase in net assets from operations		(179,302)		57,931		(1,331,009)		(936,887)
Total (decrease) increase in net assets		(179,302)		57,931		(1,331,009)		(936,887)
Net assets at end of period	\$	30,587,676	\$	31,692,476	\$	30,587,676	\$	31,692,476
Accumulated net investment loss	(\$	1,643,744)	(\$	1,876,712)	(\$	1,643,744)	(\$	1,876,712)

See accompanying notes

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

		ine months ended ptember 30, 2018		ine months ended ptember 30, 2017
Cash flows from operating activities:				
Net decrease in net assets from operations	(\$	1,331,009)	(\$	936,887)
Adjustments to reconcile net decrease in net assets to net cash and cash				
equivalents used in operating activities:				
Investments in portfolio companies		(1,365,000)		(3,900,000)
Proceeds from loan repayments		70,131		
Change in unrealized depreciation on investments		732,128		987,983
Deferred tax benefit		(220,412)		(542,917)
Realized loss on portfolio investments		1,125,673		
Depreciation and amortization		22,200		23,550
Original issue discount amortization		(29,462)		(21,085)
Non-cash conversion of debenture interest		(421,665)		(262,105)
Change in interest receivable allowance		50,342		
Changes in operating assets and liabilities:				
Decrease in interest receivable		32,772		121,675
Decrease in other assets		2,844		561,499
Increase in prepaid income taxes		(360,779)		(266,935)
Decrease in income tax payable				(320,008)
Decrease in accounts payable and accrued expenses		(69,462)		(210,173)
Decrease in profit sharing and bonus payable		(132,000)		(1,138,052)
Increase (decrease) in deferred revenue		36,234		(3,557)
Total adjustments		(526,456)		(4,970,125)
Net cash and cash equivalents used in operating activities		(1,857,465)		(5,907,012)
Net decrease in cash and cash equivalents		(1,857,465)		(5,907,012)
Cash and cash equivalents:		, , ,		, , , , ,
Beginning of period		6,262,039		12,280,140
End of period	\$	4,404,574	\$	6,373,128

See accompanying notes

4

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

September 30, 2018

(Unaudited)

	(-)	(b)			(d)(f)	
Company, Geographic Location, Business	(a) Type of	Date	(c)		Fair	Percent of Net
Description, (Industry) and Website	<u>Investment</u>	Acquired	Equity	<u>Cost</u>	<u>Value</u>	<u>Assets</u>
Non-Control/Non-Affiliate Investments 50.2% of						
net assets: (j)						
ACV Auctions, Inc. (e)(g)	1,181,160 Series A Preferred	8/12/16	<1%			0.9%
Buffalo, NY. Live mobile wholesale				* * * * * * * * * *	***	
auctions for new and used car dealers. (Software)	shares.			\$163,000	\$282,356	
www.acvauctions.com						
Centivo Corporation (e)(g)	190,967 Series A-1 Preferred	7/5/17	<1%			1.0%
New York, NY. Tech-enabled health	77 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	770717	4170			1.0 /0
solutions company that helps self-insured	shares. 337,808 Series			200,000	200,000	
employers and their	A-2 Preferred					
employees save money and have a better experience.	shares.			101,342	101,342	
(Health Care)	Total			101,542	101,542	
	Centivo			301,342	<u>301,342</u>	
www.centivo.com						
eHealth Global Technologies, Inc. (g)	\$3,500,000 Replacement					
	Term	6/28/16	0%			11.5%
Henrietta, NY. eHealth Connect® improves health	Note at 13% due December 31,					
-	2020.			3,500,000	3,500,000	
care delivery through intelligently aggregated clinical record and images for						
patient referrals.						

(Health Care) www.ehealthtechnologies.com

Č						
Empire Genomics, LLC (g)(m)	\$1,209,014 Senior Secured	6/13/14	0%			2.3%
Buffalo, NY. Molecular diagnostics company that	Convertible Term Notes at 10%					
offers a comprehensive menu of assay services for	(8% Payment in Kind (PIK)) due					
diagnosing and guiding patient therapeutic treatments. (Health Care)	December 31, 2020. \$444,916 Promissory Note			1,209,014	450,000	
www.empiregenomics.com	at 9% due December 31, 2020.			394,915	<u>252,569</u>	
	Empire			1,603,929	702,569	
GiveGab, Inc. (e)(g)	5,084,329 Series Seed Preferred	3/13/13	4%			2.0%
Ithaca, NY. Online fundraising, day of giving supporter engagement software for non-profit organizations. (Software)	shares.			616,221	616,221	
www.givegab.com						
GoNoodle, Inc. (g)(m)	\$1,000,000 Secured Note at					
Nashville, TN. Student engagement education	12% due January 31, 2020, (1%	2/6/15	<1%			3.4%
software providing core aligned physical activity breaks. (Software)	Payment in Kind (PIK)). Warrant for 47,324 Series C			1,037,070	1,037,070	
www.gonoodle.com	Preferred shares. Total			25	<u>25</u>	
	GoNoodle			1,037,095	1,037,095	
Mercantile Adjustment Bureau, LLC (g)	\$1,199,039 Subordinated Secured	10/22/12	4%			3.1%
Williamsville, NY. Full service accounts receivable management and collections company. (Contact	Note at 13% (3% for the calendar year 2018) due January 31,	10,22,12	71 //	1 100 040	040 040	3.1 70
Center) www.mercantilesolutions.com	2019. (e) \$150,000 Subordinated			1,199,040	949,040	

	Debenture at 8% due June 30, 2018. Warrant for 3.29% Membership Interests. Option			150,000	-	
	for 1.5% Membership Interests. (i) Interest receivable \$51,761.			<u>97.625</u>		
	Mercantile			1,446,665	949,040	
Outmatch Holdings, LLC (e)(g) (Chequed Holdings, LLC) Dallas, TX. Web based predictive employee selection and reference checking. (Software) www.outmatch.com	2,745,545 Class P1 Units. 109,788 Class C1 Units. Total Outmatch	11/18/10	4%	2,140,007 5,489 2,145,496	2,140,007 5,489 2,145,496	7.0%
PostProcess Technologies LLC (e)(g) Buffalo, NY. Provides innovative solutions for the post-processing of additive manufactured 3D parts. (Manufacturing) www.postprocess.com	\$300,000 Convertible Promissory Note at 5% due July 28, 2020.	7/25/16	0%	300,000	300,000	1.0%

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

September 30, 2018 (Continued)

(Unaudited)

		(b)	(c)		(d)(f)		
Company Coognaphic Lagation Dusiness	(a)	Date			Fair	Percent of Net	
Company, Geographic Location, Business <u>Description, (Industry) and Website</u>	Type of Investment	Acquired	Equity	<u>Cost</u>	<u>Value</u>	Assets	
Rheonix, Inc. (e) Ithaca, NY. Developer of fully automated	9,676 Common shares. (g) 1,839,422 Series A preferred	10/29/09	4%	-	11,000	9.6%	
microfluidic based molecular assay and diagnostic testing devices. (Health Care)	shares. (g) 50,593 Common			2,099,999	2,165,999		
www.rheonix.com	shares. (g) 589,420 Series B Preferred shares. Total			<u>702,732</u>	59,000 <u>702,732</u>		
	Rheonix			2,802,731	2,938,731		
SocialFlow, Inc. (e)(g) New York, NY. Provides instant analysis of social	1,049,538 Series B Preferred shares. 1,204,819 Series B-1	4/5/13	4%	500,000	731,431	6.8%	
networks using a proprietary, predictive analytic	Preferred shares. 717,772 Series C Preferred			750,000	839,648		
	shares.			500,000 1,750,000	500,221 2,071,300		

algorithm to optimize advertising and publishing. (Software) www.socialflow.com	Total Social Flow					
Somerset Gas Transmission Company, LLC (e) Columbus, OH. Natural gas transportation. (Oil and Gas)	26.5337 Units.	7/10/02	3%	719,097	500,000	1.6%
www.somersetgas.com Other Non-Control/Non-Affiliate Investments:						
DataView, LLC (Software) (e)	Membership Interest.	-	-	310,357	-	0.0%
UStec/Wi3 (Manufacturing) (e)	Common stock.	-	-	100,500	-	0.0%
Subtotal Non-Control/Non-Affiliate Investments						
Affiliate Investments 54.7% of net assets (k)				\$16,796,433	\$15,344,150	
BeetNPath, LLC (Grainful) (e)(g) Ithaca, NY. Frozen entrées made from 100% whole grain steel cut oats under Grainful brand name. (Consumer Product) www.grainful.com	1,119,024 Series A-2 Preferred Membership Units. 1,032,918 Series B Preferred Membership Units. \$140,000 Convertible Secured Note at 8% due December 21, 2019 Total BeetNPath	10/20/14	9%	\$359,000 261,277 140,000 760,277	\$359,000 291,000 <u>140,000</u> <u>790,000</u>	2.6%
Carolina Skiff LLC (g) Waycross, GA. Manufacturer of ocean fishing and pleasure boats. (Manufacturing)	6.0825% Class A Common Membership Interest.	1/30/04	7%	15,000	1,750,000	5.8%

www.carolinaskiff.com

ClearView Social, Inc. (e)(g) Buffalo, NY. Social media publishing tool for law, CPA and professional firms. (Software) www.clearviewsocial.com	312,500 Series Seed Plus Preferred shares.	1/4/16	6%	200,000	200,000	0.6%
First Wave Products Group, LLC (e)(g)	\$500,000 Senior Term Notes at 10%	4/19/12	7%			0.0%
Batavia, NY. Sells First Crush automated pill crusher that crushes and grinds pills for nursing	due July 31, 2017. \$280,000 Junior Term		, , e	661,563	-	0.070
homes and medical institutions. (Health Care) www.firstwaveproducts.com	Notes at 10% due July 31, 2017.			316,469	-	
w w w.mstwaveproducts.com	41,619 Capital Securities. Total First			22,000	=	
	Wave			1,000,032	=	

6

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

September 30, 2018 (Continued)

(Unaudited)

Company, Geographic Location, Business <u>Description, (Industry) and Website</u>	(a) Type of Investment	(b) Date Acquired	(c) Equity	<u>Cost</u>	(d)(f) Fair <u>Value</u>	Percent of Net <u>Assets</u>
Genicon, Inc. (g) (m) Winter Park, FL. Designs, produces and distributes patented surgical instrumentation.	1,586,902 Series B Preferred shares. \$3,000,000 Promissory Notes at 10% due May 1, 2020,	4/10/15	6%	1,000,000	1,000,000	13.7%
(Health Care) www.geniconendo.com	(8% Payment in Kind (PIK)). Warrant for 250,000 Common shares. Warrant for 125,000 Common shares. Total Genicon			3,057,327 80,000 <u>40,000</u> <u>4,177,327</u>	3,057,327 80,000 <u>40,000</u> 4,177,327	
G-TEC Natural Gas Systems (e) Buffalo, NY. Manufactures and distributes systems that allow natural gas to be used as an alternative fuel to gases. (Manufacturing) www.gas-tec.com	16.639% Class A Membership Interest. 8% cumulative dividend.	8/31/99	17%	400,000	100,000	0.3%
Knoa Software, Inc. (e)(g)(h) New York, NY. End user experience management and performance (EMP) solutions utilizing enterprise applications. (Software) www.knoa.com	973,533 Series A-1 Convertible Preferred shares. 5 1,876,922 Series B Preferred shares. Total Knoa	11/20/12	7%	750,000 <u>479,155</u> <u>1,229,155</u>	750,000 <u>479.155</u> <u>1,229.155</u>	4.0%
KnowledgeVision Systems, Inc. (g) Lincoln, MA. Online presentation and training	200,000 Series A-1 Preferred shares. 214,285 Series A-2 Preferred shares.	11/13/13	7%	250,000 300,000	300,000	4.3%

software. (Software) www.knowledgevision.com	129,033 Series A-3 Preferred shares. Warrant for 46,743 Series A-3 shares. \$75,000 Subordinated Promissory Notes at 8% payable on demand of majority of holders after August 31, 2019.(e) \$750,000 Replacement Term Note at 11% due April 30,			165,001 35,000 75,000	165,001 35,000 75,000	
	2021. Total			<u>750,000</u>	<u>_750,000</u>	
	KnowledgeVision			1,575,001	1,325,001	
Mezmeriz, Inc. (e)(g) Ithaca, NY. Micro-electronic mechanical systems (MEMS) developer of carbon fiber MEMS mirror modules for gesture recognition and 3D scanning. (Electronics Developer) www.mezmeriz.com	1,554,565 Series Seed Preferred shares.	1/9/08	14%	742,850	351,477	1.1%
Microcision LLC (g)(m) Pennsauken Township, NJ. Manufacturer of precision machined medical implants, components and assemblies. (Manufacturing) www.microcision.com	\$1,500,000 Subordinated Promissory Note at 12% (1% Payment in Kind (PIK)) due December 31, 2024. 15% Class A Common Membership Interest. Total Microcision	9/24/09	15%	1,928,532 	1,928,532 	6.3%
New Monarch Machine Tool, Inc. (g) Cortland, NY. Manufactures and services vertical/horizontal machining centers. (Manufacturing) www.monarchmt.com	22.84 Common shares.	9/24/03	15%	22,841	22,841	0.1%
OnCore Golf Technology, Inc. (e)(g)		12/31/14	9%	375,000	-	1.0%

150,000 Series AA

Preferred shares.

Buffalo, NY. Maker of patented golf balls. \$300,000

Subordinated Convertible

(Consumer Product) Promissory Notes at

10% due January

www.oncoregolf.com 24, 2018. <u>300,000</u> <u>300,000</u>

(i) Interest

receivable \$50,342.

Total OnCore <u>675,000</u> <u>300,000</u>

7

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

September 30, 2018 (Continued)

(Unaudited)

ompany, Geographic Location, Business <u>Description, (Industry) and Website</u>	(a) Type of Investment	(b) Date Acquired	(c) Equity	Cost	(d)(f) Fair <u>Value</u>	Percent of Net <u>Assets</u>
ciAps, Inc. (e)(g) Voburn, MA. Instrumentation company roducing ortable analytical devices using XRF, LIBS	187,500 Series A Preferred shares. 274,299 Series A-1 Convertible	7/12/13	6%	1,500,000	700,000	6.6%
nd	Preferred shares. 117,371 Series B Convertible			504,710	250,000	
inerals, and elements. (Manufacturing) ww.sciaps.com	Preferred shares. 113,636 Series C Convertible			250,000	250,000	
	Preferred shares. 369,698 Series C-1 Convertible			175,000	175,000	
	Preferred shares. 147,059 Series D Convertible			399,274	399,274	
	Preferred shares. Total SciAps			250,000 3,078,984	250,000 2,024,274	
OMS Technologies, LLC (e)(g) alhalla, NY. Produces and markets the icroGreen Extended Performance Oil Filter. Consumer Products) ww.microgreenfilter.com	5,959,490 Series B Membership Interests.	12/2/08	9%	472,632	30,000	0.1%
eleservices Solutions Holdings, LLC (e) (y)(m) Iontvale, NJ. Customer contact center	250,000 Class B Preferred Units. 1,000,000 Class C	5/30/14	6%	250,000	-	0.0%
pecializing in customer acquisition and	Preferred Units. 80,000 Class D			1,190,680	-	
tention or selected industries. (Contact Center)	Preferred Units. 104,198 Class E			91,200	-	
	Preferred Units.			104,198	Ξ	

ww.ipacesetters.com	PIK dividend for Series C and D at 12% and 14%, respectively. Total Teleservices			<u>1,636,078</u>	<u>=</u>	
ilson Technology Management, Inc. (g) ortland, ME. Cellular, fiber optic and ireless	120,000 Series B Preferred shares. 21,391 Series C Convertible Preferred	1/20/15	11%	600,000	600,000	8.2%
formation systems, construction, and	shares.			200,000	200,000	
lanagement. (Professional Services) ww.tilsontech.com	65,790 Series D Preferred shares. \$750,000 Subordinated Promissory			750,000	750,000	
	Note at 8% due December 1, 2022. \$200,000 Subordinated Promissory			750,000	750,000	
	Note at 8% due September 28, 2021.			200,000	200,000	
	Total Tilson			2,500,000	2,500,000	
ubtotal Affiliate Investments				\$20,413,709	\$16,728,607	
ontrol Investments 0.3% of net assets (l						
dvantage 24/7 LLC (e)(g)	45% Membership			400 700	400 700	
/illiamsville, NY. Marketing program for ine and spirits dealers. (Marketing Company) ww.advantage24-7.com	Interest.	12/30/10	45%	\$99,500	\$99,500	0.3%
Ü						
ubtotal Control Investments				\$99,500	\$99,500	
OTAL INVESTMENTS 105.2%				\$37,309,642	\$32,172,257	
THER ASSETS IN EXCESS OF IABILITIES (5.2%)					(1,584,581)	
ET ASSETS 100%					\$30,587,676	

8

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

September 30, 2018 (Continued)

(Unaudited)

Notes to the Consolidated Schedule of Portfolio Investments

- (a) At September 30, 2018, restricted securities represented 100% of the fair value of the investment portfolio. Restricted securities are subject to one or more restrictions on resale and are not freely marketable.
- (b) The Date Acquired column indicates the date in which the Corporation first acquired an investment in the company or a predecessor company.
- (c) Each equity percentage estimates the Corporation s ownership interest in the applicable portfolio investment. The estimated ownership is calculated based on the percent of outstanding voting securities held by the Corporation or the potential percentage of voting securities held by the Corporation upon exercise of warrants or conversion of debentures, or other available data. If applicable, the symbol <1% indicates that the Corporation holds an equity interest of less than one percent.
- (d) The Corporation s investments are carried at fair value in accordance with Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures, which defines fair value and establishes guidelines for measuring fair value. At September 30, 2018, ASC 820 designates 100% of the Corporation s investments as Level 3 assets. Under the valuation policy of the Corporation, unrestricted publicly held securities are valued at the average closing bid price for these securities for the last three trading days of the reporting period. Restricted securities are subject to restrictions on resale, and are valued at fair value as determined by the management of the Corporation and submitted to the Board of Directors for approval. Fair value is considered to be the amount that the Corporation may reasonably expect to receive for portfolio securities when sold on the valuation date. Valuations as of any particular date, however, are not necessarily indicative of amounts which may ultimately be realized as a result of future sales or other dispositions of securities and these favorable or unfavorable differences could be material. Among the factors considered in determining the fair value of restricted securities are the financial condition and operating results, projected operations, and other analytical data relating to the investment. Also considered are the market prices for unrestricted securities of the same class (if applicable) and other matters which may have an impact on the value of the portfolio company (see Note 3 Investments to the Consolidated Financial Statements).
- (e) These investments are non-income producing. All other investments are income producing. Non-income producing investments have not generated cash payments of interest or dividends including LLC tax-related distributions within the last twelve months, or are not expected to do so going forward.
- (f) As of September 30, 2018 the total cost of investment securities was approximately \$37.3 million. Net unrealized depreciation was approximately (\$5.1) million, which was comprised of \$2.3 million of unrealized appreciation of investment securities and (\$7.4) million of unrealized depreciation of investment securities. At September 30, 2018, the aggregate gross unrealized gain for federal income tax purposes was \$2.6 million and the aggregate gross unrealized loss for federal income tax purposes was (\$6.5) million. The net unrealized loss for federal income tax

purposes was (\$3.9) million based on a tax cost of \$36.1 million.

- (g) Rand Capital SBIC, Inc. investment.
- (h) Reduction in cost and value from previously reported balances reflects current principal repayment.
- (i) Represents interest due (amounts over \$50,000) from investments included as interest receivable on the Corporation s Statement of Financial Position.
- (j) Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments.
- (k) Affiliate Investments are defined by the Investment Company Act of 1940, as amended (1940 Act), as those Non-Control investments in companies in which between 5% and 25% of the voting securities are owned by the Corporation.
- (l) Control Investments are defined by the 1940 Act as investments in companies in which more than 25% of the voting securities are owned by the Corporation or where greater than 50% of the board representation is maintained.
- (m) Payment in kind (PIK) represents earned interest that is added to the cost basis of the investment.

9

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

September 30, 2018 (Continued)

(Unaudited)

Investments in and Advances to Affiliates

Company	Type of Investment	December 31, 2017 Fair ValueA	Gross	Gross Reductions	September 30, 2018 Fair Value	Net Realized Gains (Losses)	Amount of Interest/ Dividend/ Fee Income (3)
Control Investments:							
Advantage 24/7 LLC	45% Membership interest.	\$99,500	\$-	\$-	\$99,500	\$-	\$-
	Total Control Investments	\$99,500	\$ -	\$-	\$99,500	\$-	\$ -
Affiliate Investme	nts:	. ,	·	·	. ,	·	
BeetNPath, LLC	1,119,024 Series A-2 Preferred Membership Units. 1,032,918 Series B Preferred Membership	\$359,000	\$-	\$-	\$359,000	\$- -	\$-
	Units. \$140,000 convertible secured	291,000	-	-	291,000	=	-
	note at 8% Total BeetNPath	<u>-</u> 650,000	140,000 140,000	=	140,000 790,000	=	2,551 2,551
Carolina Skiff LLC	6.0825% Class A common membership				-		
	interest.	1,750,000	-	-	1,750,000	-	119,433
		200,000	-	-	200,000	-	-

ClearView Social, Inc.	312,500 Series seed plus preferred shares.						
First Wave Products Group, LLC	\$500,000 senior term notes at 10%. \$280,000 junior term notes at 10%. Warrant for 41,619 capital securities. Total First Wave	250,000 - - 250,000	- - - - -	(250,000) (250,000)	- - - - -	- - = =	- - - - -
Genicon, Inc.	1,586,902 Series B preferred shares. \$3,000,000 promissory notes at 8%. Warrant for 250,000 common shares Warrant for 125,000 common shares Total Genicon	1,000,000 2,903,779 80,000 40,000 4,023,779	153,548 - - - 153,548	- - - - =	1,000,000 3,057,327 80,000 40,000 4,177,327	- - - - =	251,069 - - - 251,069
GiveGab, Inc.	5,084,329 Series Seed preferred shares.	424,314	191,907	(616,221)	-	-	-
G-TEC Natural Gas Systems	16.639% Class A membership interest. 8% cumulative dividend.	100,000	_	_	100,000	_	_
Intrinsiq Materials, Inc.	4,161,747 Series A preferred shares.	400,000	-	(400,000)	-	(1,125,673)	-
Knoa Software, Inc.	973,533 Series A-1 convertible preferred shares. 1,876,922 Series B preferred shares. \$48,466 convertible promissory note at 8%.	750,000 479,155 <u>48,466</u> 1,277,621	-	- (48,466) (48,466)	750,000 479,155 - 1,229,155	- - - -	- - <u>773</u> <u>773</u>
KnowledgeVision							
Systems, Inc.	preferred shares. 214,285 Series A-2	-	-	-	-	-	-
	preferred shares. 129,033 Series A-3 preferred shares.	300,000 165,001	-	-	300,000 165,001	-	-

Edgar Filing: RAND CAPITAL CORP - Form 10-Q

	\$75,000 subordinated promissory notes at 8% \$750,000 replacement term note at 11% Warrant for 46,743 Series A-3 shares. Total Knowledge Vision	50,000 - 35,000 550,001	25,000 750,000 	- - - -	75,000 750,000 35,000 1,325,001	- - - =	3,896 37,571
Mezmeriz, Inc.	1,554,565 Series seed preferred shares.	351,477	_		351,477	_	-
Microcision LLC	\$1,500,000 subordinated promissory note at 12% (1% PIK).	1,914,140	14,392	-	1,928,532	-	172,704
New Monarch Machine Tool, Inc.	22.84 common shares.	22,841	-	-	22,841	-	29,409

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

September 30, 2018 (Continued)

(Unaudited)

Investments in and Advances to Affiliates

Company	Type of Investment	December 31, 2017 Fair Value	Gross Additions (1)	Gross Reductions (2)	September 30, 2018 Fair Value	Net Realized Gains (Losses)	Amount of Interest/ Dividend/ Fee Income (3)
OnCore Golf Technology, Inc.	150,000 Series AA preferred shares. \$300,000 subordinated convertible promissory notes at	200.000	-	-	-	-	-
	6%. Total OnCore	300,000 300,000	<u> </u>	<u> </u>	300,000 300,000	_ 	<u> </u>
SciAps, Inc.	187,500 Series A convertible preferred shares. 274,299 Series A-1 convertible preferred shares. 117,371 Series B convertible preferred	700,000 250,000	-	-	700,000 250,000	-	-
	shares. 113,636 Series C	250,000	-	-	250,000	-	-
	preferred shares. 369,698 Series C-1	175,000	-	-	175,000	-	-
	preferred shares. 147,059 Series D	399,274	-	-	399,274	-	-
	shares Total SciAps	1,774,274	250,000 250,000	=	<u>250,000</u> <u>2,024,274</u>	=======================================	<u>=</u> =
SOMS		528,348	-	(498,348)	30,000	-	-

Edgar Filing: RAND CAPITAL CORP - Form 10-Q

Technologies, LLC	5,959,490 Series B membership interests.						
Teleservices	250,000 Class B						
Solutions	preferred units. 1,000,000 Class C	-	-	-	-	-	-
Holdings,	preferred units. 80,000 Class D	-	-	-	-	-	-
LLC	preferred units. 104,198 Class E	-	-	-	-	-	-
	preferred units. Total	=	=	Ξ	Ξ	=	=
	Teleservices	Ξ	Ξ	Ξ	Ξ	Ξ	Ξ
Tilson Technology Management, Inc.	120,000 Series B preferred shares. 21,391 Series C convertible	600,000	-	-	600,000	-	15,000
	preferred shares. \$200,000 subordinated	200,000	-	-	200,000	-	-
	promissory note at 8%.	200,000	-	-	200,000	-	11,967
	65,790 Series D preferred shares. \$750,000 subordinated	750,000	-	-	750,000	-	14,064
	promissory note at 8%. Total Tilson	<u>750,000</u> 2,500,000	<u> </u>	<u>=</u>	<u>750,000</u> 2,500,000	<u>=</u>	44,877 85,908
	Total Affiliate		_	_		_	
	Investments	\$17,016,795	\$1,524,847	(\$1,813,035)	\$16,728,607	(\$1,125,673)	\$703,314
	Total Control and Affiliate						
	Investments	\$17,116,295	\$1,524,847	(\$1,813,035)	\$16,828,107	(\$1,125,673)	\$703,314

This schedule should be read in conjunction with the Corporation s Consolidated Financial Statements, including the Consolidated Schedule of Portfolio Investments and Notes to the Consolidated Financial Statements.

- (1) Gross additions include increases in the cost basis of investments resulting from new portfolio investments, follow on investments, capitalized interest and the accretion of discounts. Gross additions also include net increases in unrealized appreciation or net decreases in unrealized depreciation, and the movement of an existing portfolio company into this category and out of another category.
- (2) Gross reductions include decreases in the cost basis of investments resulting from principal repayments, sales, note conversions, net increases in unrealized depreciation, net decreases in unrealized appreciation, the exchange of existing securities for new securities and the movement of an existing portfolio company out of this category and into

another category.

(3) Represents the total amount of interest, fees or dividends credited to income for the portion of the period an investment was included in Control or Affiliate categories, respectively.

11

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

September 30, 2018 (Continued)

(Unaudited)

Industry Classification	Percentage of Total Investments (at fair value) as of September 30, 2018
Healthcare	36.1%
Software	27.7
Manufacturing	19.0
Professional Services	7.8
Consumer Product	3.5
Contact Center	2.9
Oil and Gas	1.6
Electronics	1.1
Marketing	0.3
Total Investments	100%

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

December 31, 2017

	(a)	(b)	(c)		(d)(f)	Percent
Company, Geographic Location, Business		Date			Fair	of Net
Description, (Industry) and Website	Type of Investment	Acquired	Equity	Cost	<u>Value</u>	<u>Assets</u>
Non-Control/Non-Affiliate Investments 47.5% of net assets: (j)						
ACV Auctions, Inc. (e)(g) Buffalo, NY. Live mobile wholesale auctions for new and used car dealers. (Software) www.acvauctions.com	1,181,160 Series A preferred shares.	8/12/16	<1%	\$163,000	\$282,356	0.9%
Centivo Corporation (e)(n) New York, NY. Tech-enabled health solutions company that helps self-insured employers and their employees save money and have a better experience. (Health Care)	\$100,000 convertible unsecured note at 2% due February 1, 2019.	7/5/17	0%	100,000	100,000	0.3%
eHealth Global Technologies, Inc. Henrietta, NY. eHealth Connect® improves health care delivery through intelligently aggregated clinical record and images for patient referrals. (Health Care) www.ehealthtechnologies.com	(g) \$1,500,000 term note at 10% due September 2, 2019. (n) \$2,000,000 term note at 10% due September 2, 2019. Total eHealth	6/28/16	0%	1,500,000 2,000,000 3,500,000	1,500,000 2,000,000 3,500,000	11.0%
Empire Genomics, LLC (g) Buffalo, NY. Molecular diagnostics	\$1,101,489 senior secured convertible term	6/13/14	0%			4.2%

company that offers a comprehensive menu of assay services for	notes at 10% due April 30, 2018.			1,101,489	1,101,489	
diagnosing and guiding patient therapeutic treatments.	\$250,000 promissory note at 12%			, ,	, ,	
(Health Care)	due December 31, 2019.			250,000	250,000	
www.empiregenomics.com	(i) Interest receivable \$65,906. Total Empire			1,351,489	1,351,489	
GoNoodle, Inc. (g)(m)	\$1,000,000 secured note at 12%	2/6/15	<1%			3.2%
(Formerly HealthTeacher, Inc.)	due January 31, 2020, (1%	2/0/13	\1 / <i>t</i>			3.2 70
Nashville, TN. Student engagement education	Payment in Kind (PIK)).			1,029,330	1,029,330	
software providing core aligned physical activity	Warrant for 47,324 Series C			2.5		
breaks. (Software) www.gonoodle.com	Preferred shares. Total GoNoodle			25 1,029,355	25 1,029,355	
Mercantile Adjustment Bureau, LLC (g)	\$1,199,039 subordinated	10/02/12	4.07			2.00
Williamsville, NY. Full service accounts receivable	secured note at 13% (3% for the calendar	10/22/12	4%			3.0%
management and collections company.	year 2017) due January 31, 2018.			1,199,040	949,040	
(Contact Center)	(e) \$150,000 subordinated					
www.mercantilesolutions.com	debenture at 8% due June 30, 2018.			150,000		
	Warrant for 3.29% membership			150,000	-	
	interests. Option for 1.5%					
	membership interests.			97,625		
	(i) Interest receivable \$55,983. Total Mercantile			<u>1,446,665</u>	<u>949,040</u>	
Outmatch Holdings, LLC (e)(g)	2,641,899 Class P1	11/19/10	A 07-			6 70%
(Chequed Holdings, LLC)	Units. 109,788 Class C1 Units.	11/18/10	4%	2,140,007 5,489	2,140,007 5,489	6.7%
Dallas, TX. Web based predictive employee selection	Total Outmatch			2,145,496	2,145,496	
and reference checking. (Software)	Total Outmattl			<u> </u>	<u>2,17J,77U</u>	

www.outmatch.com

PostProcess Technologies LLC (e)(g)	\$300,000 convertible promissory	7/25/16	0%			0.9%
Buffalo, NY. Provides innovative solutions for the	note at 5% due July 28, 2018.			300,000	300,000	
post-processing of additive manufactured 3D parts.				,		
(Manufacturing) www.postprocess.com						

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

December 31, 2017 (Continued)

	(a)	(b)	(c)		(d)(f)	Percent
Company, Geographic Location, Business		Date			Fair	of Net
Description, (Industry) and Website	Type of Investment	Acquired	Equity	<u>Cost</u>	<u>Value</u>	<u>Assets</u>
Rheonix, Inc. (e) Ithaca, NY. Developer of fully automated	9,676 common shares. (g) 1,839,422 Series A preferred	10/29/09	4%	-	11,000	9.2%
microfluidic based molecular assay and diagnostic testing devices. (Health Care)	shares. (g) 50,593 common			2,099,999	2,165,999	
www.rheonix.com	shares. (g) 589,420 Series B			-	59,000	
	preferred shares. Total Rheonix			702,732 2,802,731	702,732 2,938,731	
SocialFlow, Inc. (e)(g) New York, NY. Provides instant analysis of	1,049,538 Series B preferred shares. 1,204,819 Series	4/5/13	4%	500,000	731,431	6.5%
social	B-1 preferred shares. 717,772 Series C			750,000	839,648	
networks using a proprietary, predictive analytic algorithm to optimize advertising and	preferred shares.			_500,000	500,221	
publishing. (Software) www.socialflow.com	Total Social Flow			1,750,000	2,071,300	
Somerset Gas Transmission Company, LLC (e) Columbus, OH. Natural gas transportation. (Oil and Gas) www.somersetgas.com	26.5337 units.	7/10/02	3%	719,097	500,000	1.6%
Other Non-Control/Non-Affiliate Investments:						
DataView, LLC (Software) (e)	Membership Interest.	-	-	310,357	-	0.0%
UStec/Wi3 (Manufacturing) (e)	Common Stock.	-	-	100,500	-	0.0%
Table of Contents						35

Subtotal Non-Control/Non-Affiliate Investments						
Affiliate Investments 53.3% of net assets (k)				\$15,718,690	\$15,167,767	
BeetNPath, LLC (Grainful) (e)(g) Ithaca, NY. Frozen entrées and packaged dry side dishes made from 100% whole grain steel	1,119,024 Series A-2 Preferred Membership Units. 1,032,918 Series B	10/20/14	9%	\$359,000	\$359,000	2.0%
cut oats under Grainful brand name. (Consumer Product) www.grainful.com	Preferred Membership Units. Total BeetNPath			261,277 620,277	291,000 650,000	
Carolina Skiff LLC (g) Waycross, GA. Manufacturer of fresh water, ocean fishing and pleasure boats. (Manufacturing) www.carolinaskiff.com	6.0825% Class A common membership interest.	1/30/04	7%	15,000	1,750,000	5.5%
ClearView Social, Inc. (e)(g) Buffalo, NY. Social media publishing tool for law, CPA and professional firms. (Software) www.clearviewsocial.com	312,500 Series seed plus preferred shares.	1/4/16	6%	200,000	200,000	0.6%
First Wave Products Group, LLC (e)(g) Batavia, NY. Sells First Crush automated pill crusher that crushes and grinds medical pills for	\$500,000 senior term notes at 10% due July 31, 2017. \$280,000 junior term notes at 10% due	4/19/12	7%	661,563	250,000	0.8%
nursing homes and medical institutions. (Health Care) www.firstwaveproducts.com	July 31, 2017. Warrant for 41,619 capital securities. Total First Wave			316,469 <u>22,000</u> <u>1,000,032</u>	<u>-</u> 250,000	
Genicon, Inc. Winter Park, FL. Designs, produces and	(g) 1,586,902 Series B preferred shares. (g) \$2,000,000 promissory note at 8%	4/10/15	6%	1,000,000	1,000,000	12.6%
distributes patented surgical instrumentation.	due May 1, 2020.			1,936,002	1,936,002	

Edgar Filing: RAND CAPITAL CORP - Form 10-Q

(Health Care)	(g) Warrant for			
	250,000 common			
www.geniconendo.com	shares.	80,000	80,000	
	(n) \$1,000,000			
	promissory note at			
	8%			
	due May 1, 2020.	967,777	967,777	
	(n) Warrant for			
	125,000 common			
	shares.	40,000	40,000	
	Total Genicon	4,023,779	4,023,779	

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

December 31, 2017 (Continued)

	(a)	(b)	(c)		(d)(f)	Percent
Company, Geographic Location, Business		Date			Fair	of Net
Description, (Industry) and Website	Type of Investment	Acquired	Equity	<u>Cost</u>	Value	<u>Assets</u>
GiveGab, Inc. (e)(g) Ithaca, NY. Online fundraising, day of giving supporter engagement software for non-profit organizations. (Software) www.givegab.com	5,084,329 Series Seed preferred shares.	3/13/13	6%	616,221	424,314	1.3%
G-TEC Natural Gas Systems (e) Buffalo, NY. Manufactures and distributes systems that allow natural gas to be used as an alternative fuel to gases. (Manufacturing) www.gas-tec.com	16.639% Class A membership interest. 8% cumulative dividend.	8/31/99	17%	400,000	100,000	0.3%
Intrinsiq Materials, Inc. (e)(g) Rochester, NY. Produces printable electronics utilizing a unique process of nanomaterial based ink in a room-temperature environment. (Manufacturing) www.intrinsiqmaterials.com	4,161,747 Series A preferred shares.	9/19/13	12%	1,125,673	400,000	1.3%
Knoa Software, Inc. (g) New York, NY. End user experience management and performance (EMP) solutions Table of Contents	973,533 Series A-1 convertible preferred shares. 1,876,922 Series B preferred shares.	11/20/12	7%	750,000 479,155	750,000 479,155	4.0%

utilizing enterprise applications. (Software) www.knoa.com	\$48,466 convertible promissory note at 8% due May 9, 2018. Total Knoa			48,466 1,277,621	48,466 1,277,621	
KnowledgeVision Systems, Inc. (e)(g) Lincoln, MA. Online presentation and training software. (Software) www.knowledgevision.com	200,000 Series A-1 preferred shares. 214,285 Series A-2 preferred shares. 129,033 Series A-3 preferred shares. Warrant for 46,743 Series A-3 shares. \$50,000 subordinated promissory note at 8% payable on demand of majority of noteholders after August 31, 2017. Total KnowledgeVision	11/13/13	7%	250,000 300,000 165,001 35,000 	300,000 165,001 35,000 <u>50,000</u>	1.7%
Mezmeriz, Inc. (e)(g) Ithaca, NY. Micro-electronic mechanical systems (MEMS) developer of carbon fiber MEMS mirror modules for gesture recognition and 3D scanning. (Electronics Developer) www.mezmeriz.com	1,554,565 Series Seed preferred shares.	1/9/08	14%	742,850	351,477	1.1%
Microcision LLC (g)(m) Pennsauken Township, NJ. Manufacturer of precision machined medical implants, components and assemblies. (Manufacturing) www.microcision.com	\$1,500,000 subordinated promissory note at 12% (1% PIK) due December 31, 2024. 15% Class A common membership interest. Total Microcision	9/24/09	15%	1,914,140 	1,914,140 1,914,140	6.0%
New Monarch Machine Tool, Inc. (g) Cortland, NY. Manufactures and services vertical/horizontal machining centers.	22.84 common shares.	9/24/03	15%	22,841	22,841	0.1%

(Manufacturing) www.monarchmt.com

15

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

December 31, 2017 (Continued)

	(a)	(b)	(c)		(d)(f)	Percent
Company, Geographic Location, Business		Date			Fair	of Net
Description, (Industry) and Website	Type of Investment	Acquired	Equity	Cost	<u>Value</u>	<u>Assets</u>
OnCore Golf Technology, Inc. (e)(g) Buffalo, NY. Maker of patented golf balls. Consumer Product) www.oncoregolf.com	150,000 Series AA preferred shares. \$300,000 subordinated convertible promissory notes at 6% (10% for calendar year 2017) due January 24, 2018. (i) Interest receivable \$50,342.	12/31/14	9%	375,000 300,000 675,000	<u>300,000</u>	0.9%
SciAps, Inc. (e)(g)	Total OnCore 187,500 Series A			<u>675,000</u>	300,000	
Woburn, MA. Instrumentation company producing portable analytical devices using KRF, LIBS and RAMAN spectroscopy to identify compounds, minerals, and elements. Manufacturing) www.sciaps.com	convertible preferred shares. 274,299 Series A-1 convertible preferred shares. 117,371 Series B convertible preferred shares. 113,636 Series C preferred shares. 369,698 Series C-1 preferred shares. Total SciAps	7/12/13	8%	1,500,000 504,710 250,000 175,000 399,274 2,828,984	700,000 250,000 250,000 175,000 399,274 1,774,274	5.6%
SOMS Technologies, LLC (e)(g) Valhalla, NY. Produces and markets the	5,959,490 Series B membership interests.	12/2/08	9%	472,632	528,348	1.7%

nicroGreen Extended Performance Oil Filter. Consumer Products) www.microgreenfilter.com						
Teleservices Solutions Holdings, LLC (e)	250,000 Class B					
[g)(m)	preferred units. 1,000,000 Class C preferred units.	5/30/14	6%	250,000 1,190,680	-	0.0%
Montvale, NJ. Customer contact center	80,000 Class D preferred units.			91,200	-	
specializing in customer acquisition and etention for selected industries. (Contact Center)	104,198 Class E preferred units. PIK dividend for Series C and D at 12%			<u>104,198</u>	Ξ	
www.ipacesetters.com	and 14%, respectively. Total Teleservices			<u>1,636,078</u>	Ξ.	
Portland, ME. Cellular, fiber optic and wireless	(g) 120,000 Series B preferred shares. 21,391 Series C convertible	1/20/15	11%	600,000	600,000	7.8%
nformation systems, construction, and nanagement. (Professional Services)	preferred shares. (g) \$200,000 subordinated promissory			200,000	200,000	
www.tilsontech.com	note at 8% due September 28, 2021.			200,000	200,000	
	(n) 65,790 Series D preferred shares. (n) \$750,000 subordinated promissory			750,000	750,000	
	note at 8% due December 1, 2022. Total Tilson			_750,000 2,500,000	_750,000 2,500,000	
Subtotal Affiliate Investments				\$20,871,129	\$17,016,795	
Control Investments 0.3% of net assets 1)						
Advantage 24/7 LLC (e)(g)	53% Membership interest.	12/30/10	53%	\$99,500	\$99,500	0.3%
Williamsville, NY. Marketing program for wine and spirits dealers. (Marketing Company) www.advantage24-7.com			•		,	
Subtotal Control Investments				\$99,500	\$99,500	

FOTAL INVESTMENTS 101.1% \$36,689,319 \$32,284,062

OTHER ASSETS IN EXCESS OF LIABILITIES (1.1%)

(365,377)

NET ASSETS 100% \$31,918,685

16

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

December 31, 2017 (Continued)

Notes to the Consolidated Schedule of Portfolio Investments

- (a) At December 31, 2017, restricted securities represented 100% of the fair value of the investment portfolio. Restricted securities are subject to one or more restrictions on resale and are not freely marketable.
- (b) The Date Acquired column indicates the date in which the Corporation first acquired an investment in the company or a predecessor company.
- (c) Each equity percentage estimates the Corporation s ownership interest in the applicable portfolio investment. The estimated ownership is calculated based on the percent of outstanding voting securities held by the Corporation or the potential percentage of voting securities held by the Corporation upon exercise of warrants or conversion of debentures, or other available data. If applicable, the symbol <1% indicates that the Corporation holds an equity interest of less than one percent.
- (d) The Corporation s investments are carried at fair value in accordance with Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures, which defines fair value and establishes guidelines for measuring fair value. At December 31, 2017, ASC 820 designates 100% of the Corporation s investments as Level 3 assets. Under the valuation policy of the Corporation, unrestricted publicly held securities are valued at the average closing bid price for these securities for the last three trading days of the reporting period. Restricted securities are subject to restrictions on resale, and are valued at fair value as determined by the management of the Corporation and submitted to the Board of Directors for approval. Fair value is considered to be the amount that the Corporation may reasonably expect to receive for portfolio securities when sold on the valuation date. Valuations as of any particular date, however, are not necessarily indicative of amounts which may ultimately be realized as a result of future sales or other dispositions of securities and these favorable or unfavorable differences could be material. Among the factors considered in determining the fair value of restricted securities are the financial condition and operating results, projected operations, and other analytical data relating to the investment. Also considered are the market prices for unrestricted securities of the same class (if applicable) and other matters which may have an impact on the value of the portfolio company (see Note 3 Investments to the Consolidated Financial Statements).
- (e) These investments are non-income producing. All other investments are income producing. Non-income producing investments have not generated cash payments of interest or dividends including LLC tax-related distributions within the last twelve months, or are not expected to do so going forward.
- (f) As of December 31, 2017, the total cost of investment securities was approximately \$36.7 million. Net unrealized depreciation was approximately (\$4.4) million, which was comprised of \$2.4 million of unrealized appreciation of investment securities and (\$6.8) million of unrealized depreciation of investment securities. At December 31, 2017, the aggregate gross unrealized gain for federal income tax purposes was \$2.8 million and the aggregate gross unrealized loss for federal income tax purposes was (\$4.4) million. The net unrealized loss for federal income tax purposes was (\$1.6) million based on a tax cost of \$33.9 million.

- (g) Rand Capital SBIC, Inc. investment.
- (h) Reduction in cost and value from previously reported balances reflects current principal repayment. There were no principal repayments during the year ended December 31, 2017.
- (i) Represents interest due (amounts over \$50,000) from investments included as interest receivable on the Corporation s Statement of Financial Position.
- (j) Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments.
- (k) Affiliate Investments are defined by the Investment Company Act of 1940, as amended (1940 Act), as those Non-Control investments in companies in which between 5% and 25% of the voting securities are owned by the Corporation.
- (1) Control Investments are defined by the 1940 Act as investments in companies in which more than 25% of the voting securities are owned by the Corporation or where greater than 50% of the board representation is maintained.
- (m) Payment in kind (PIK) represents earned interest that is added to the cost basis of the investment.
- (n) Rand Capital SBIC II, L.P. investment.

17

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

December 31, 2017 (Continued)

Investments in and Advances to Affiliates

Company	Type of Investment	December 31, 2016 Fair Value	Gross Additions (1)	Gross Reductions (2)	December 31, 2017 Fair Value	Realized r Gains	
Control Investments:							
Advantage 24/7 LLC	53% Membership interest.	\$99,500	\$-	\$-	\$99,500	\$-	\$-
	Total Control Investments	\$99,500	\$-	\$-	\$99,500	-	\$-
Affiliate Investments:							
BeetNPath, LLC	1,119,024 Series A-2 Preferred Membership Units. 1,032,918 Series B Preferred Membership Units \$150,000 convertible promissory note at 8%.	\$359,000 - 150,000	\$291,000	\$- (150,000)	\$359,000 291,000	-	\$- - 4,800
	Total BeetNPath	509,000	<u>291,000</u>	(150,000)	650,000		4,800
Carolina Skiff LLC	6.0825% Class A common membership interest.	1,100,000	650,000	-	1,750,000	-	178,532
ClearView Social, Inc.	312,500 Series seed plus preferred shares.	200,000	-	-	200,000	_	_
First Wave Products	\$500,000 senior term notes at	250,000	-	-	250,000	-	-

Group, LLC	10%. \$280,000 junior term notes at 10%. Warrant for 41,619 capital securities.	- 	-	-	- 	-	-
	Total First Wave	250,000	_	_	250,000	_	-
Genicon, Inc.	1,586,902 Series B preferred shares. \$1,100,000 senior	1,000,000	-	-	1,000,000	-	-
	term loans at 12%. \$600,000 term	1,100,000	-	(1,100,000)	-	-	50,234
	loan at 14%. \$2,000,000	600,000	-	(600,000)	-	-	32,200
	promissory note at 8% \$1,000,000	-	2,016,002	(80,000)	1,936,002	-	129,752
	promissory note at 8% Warrant for	-	1,007,777	(40,000)	967,777	-	60,860
	250,000 common shares Warrant for 125,000 common	-	80,000	-	80,000	-	
	shares Total Genicon	<u>-</u> 2,700,000	40,000 3,143,779	<u>-</u> (1,820,000)	<u>40,000</u> <u>4,023,779</u>	<u> </u>	<u>-</u> <u>-</u> <u>273,046</u>
GiveGab, Inc.	5,084,329 Series Seed preferred shares.	424,314	-	-	424,314	_	-
G-TEC Natural Gas Systems	16.639% Class A membership interest. 8% cumulative dividend	100,000	-	<u>-</u>	100,000	_	-
Intrinsiq Materials, Inc.	4,161,747 Series A preferred shares.	780,000	-	(380,000)	400,000	-	-
Knoa Software, Inc.	973,533 Series A-1 convertible preferred shares. 1,876,922 Series B	-	750,000	-	750,000	-	-
	preferred shares. \$48,466	449,455 _48,466	29,700 	- =	479,155 <u>48,466</u>	-	<u>3,877</u>

Edgar Filing: RAND CAPITAL CORP - Form 10-Q

convertible promissory note at 8%. Total Knoa	<u>497,921</u>	<u>779,700</u>	=	<u>1,277,621</u>	Ξ	<u>3,877</u>
200,000 Series A-1 preferred						
214,285 Series	-	-	-	-	-	-
shares. 129,033 Series	300,000	-	-	300,000	-	-
shares. \$50,000 subordinated	165,001	-	-	165,001	-	-
at 8% Warrant for	-	50,000	-	50,000	-	3,748
A-3 shares. Total	<u>35,000</u>		=	<u>35,000</u>	Ξ	
Vision	500,001	<u>50,000</u>	=	<u>550,001</u>	Ξ.	<u>3,748</u>
1,554,565 Series seed preferred shares.	351,477	-	-	351,477	_	-
\$1,500,000 subordinated promissory note						
at 12% (1% PIK).	1,891,964	22,176	-	1,914,140	-	228,239
22.84 common shares.	22,841	-	-	22,841	-	28,409
	promissory note at 8%. Total Knoa 200,000 Series A-1 preferred shares. 214,285 Series A-2 preferred shares. 129,033 Series A-3 preferred shares. \$50,000 subordinated promissory note at 8% Warrant for 46,743 Series A-3 shares. Total Knowledge Vision 1,554,565 Series seed preferred shares. \$1,500,000 subordinated promissory note at 12% (1% PIK).	promissory note at 8%. Total Knoa 497,921 200,000 Series A-1 preferred shares 214,285 Series A-2 preferred shares. 300,000 129,033 Series A-3 preferred shares. 165,001 \$50,000 subordinated promissory note at 8% - Warrant for 46,743 Series A-3 shares. 35,000 Total Knowledge Vision 500,001 1,554,565 Series seed preferred shares. 351,477 \$1,500,000 subordinated promissory note at 12% (1% PIK). 1,891,964 22.84 common 22,841	Total Knoa 497,921 779,700 200,000 Series A-1 preferred shares 214,285 Series A-2 preferred shares. 300,000 - 129,033 Series A-3 preferred shares. 165,001 - \$50,000 subordinated promissory note at 8% - 50,000 Warrant for 46,743 Series A-3 shares. 35,000 - Total Knowledge Vision 500,001 50,000 1,554,565 Series seed preferred shares. 351,477 - \$1,500,000 subordinated promissory note at 12% (1% PIK). 1,891,964 22,176	Total Knoa 497,921 779,700 = 200,000 Series A-1 preferred shares 214,285 Series A-2 preferred shares. 300,000 129,033 Series A-3 preferred shares. 165,001 \$50,000 subordinated promissory note at 8% - 50,000 - Warrant for 46,743 Series A-3 shares. 35,000 Total Knowledge Vision 500,001 50,000 = 1,554,565 Series seed preferred shares. 351,477 \$1,500,000 subordinated promissory note at 12% (1% PIK). 1,891,964 22,176 - 22.84 common 22,841 -	promissory note at 8%. Total Knoa 497,921 779,700 = 1,277,621 200,000 Series A-1 preferred shares.	promissory note at 8%. Total Knoa 497.921 779.700 = 1.277.621 = 200,000 Series A-1 preferred shares.

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

December 31, 2017 (Continued)

Investments in and Advances to Affiliates

Com		Type of Investment	December 31, 2016 Fair Value	Gross Additions (1)	Gross Reductions (2)	December Ro 31, 2017 Fair C Value (I	ealized Gains	
OnCor Techno Inc.	re Golf	150,000 Series AA preferred shares. \$300,000 subordinated convertible promissory notes	-	-	-	-	-	-
		at 6%. Total OnCore	300,000 300,000	=	<u> </u>	300,000 300,000	= =	29,211 29,211
SciAps	s, Inc.	187,500 Series A convertible preferred shares. 274,299 Series A-1 convertible	1,000,000	-	(300,000)	700,000	-	-
		preferred shares. 117,371 Series B convertible preferred	504,710	-	(254,710)	250,000	-	-
		shares. 113,636 Series C	250,000	-	-	250,000	-	-
		preferred shares. 369,698 Series C-1 preferred	-	175,000	-	175,000	-	-
		shares. \$200,000 subordinated promissory note at	-	399,274	-	399,274	-	-
		10%.	200,000	-	(200,000)	-	-	4,731

Edgar Filing: RAND CAPITAL CORP - Form 10-Q

	Total Control and Affiliate Investments	\$13,705,474	\$7,010,929	(\$3,600,108)	\$17,116,295	\$ -	\$805,668
	Total Affiliate Investments	\$13,605,974	\$7,010,929	(\$3,600,108)	\$17,016,795	\$-	\$805,668
	8%. Total Tilson	1,000,000	1,500,000	=	2,500,000	=	42,675
	preferred shares. \$750,000 subordinated promissory note at	_	<u>750,000</u>	_	_750,000	_	_5,096
	\$200,000 subordinated promissory note at 8%. 65,790 Series D	200,000	750,000	-	200,000 750,000	-	16,000 1,579
Technology Management, Inc.	preferred shares. 21,391 Series C convertible preferred shares.	200,000	-	-	200,000	-	20,000
Tilson	120,000 Series B		_	(373,370)		_	-
	preferred units. Total Teleservices	104,198 395,398		(104,198) (395,398)	=	=	=
LLC	preferred units. 104,198 Class E	91,200	-	(91,200)	-	-	-
Solutions Holdings,	preferred units. 1,000,000 Class C preferred units. 80,000 Class D	200,000	-	(200,000)	-	-	-
Technologies, LLC Teleservices	5,959,490 Series B membership interests.	528,348	-	-	528,348	-	6,024
SOMS	\$100,000 secured subordinated convertible note at 10%. Total SciAps	_100,000 2,054,710	<u>-</u> - <u>574,274</u>	(100,000) (854,710)		=======================================	2,376 7,107

This schedule should be read in conjunction with the Corporation s Consolidated Financial Statements, including the Consolidated Schedule of Portfolio Investments and Notes to the Consolidated Financial Statements.

⁽¹⁾ Gross additions include increases in the cost basis of investments resulting from new portfolio investments, follow on investments, capitalized interest and the accretion of discounts. Gross additions also include net increases in

unrealized appreciation or net decreases in unrealized depreciation, and the movement of an existing portfolio company into this category and out of another category.

- (2) Gross reductions include decreases in the cost basis of investments resulting from principal repayments, sales, note conversions, net increases in unrealized depreciation, net decreases in unrealized appreciation, the exchange of existing securities for new securities and the movement of an existing portfolio company out of this category and into another category.
- (3) Represents the total amount of interest, fees or dividends credited to income for the portion of the period an investment was included in Control or Affiliate categories, respectively.

19

RAND CAPITAL CORPORATION AND SUBSIDIARIES

CONSOLIDATED SCHEDULE OF PORTFOLIO INVESTMENTS

December 31, 2017 (Continued)

Industry Classification	Percentage of Total Investments (at fair value) as of December 31, 2017
Healthcare	37.7%
Software	24.7
Manufacturing	19.4
Professional Services	7.7
Consumer Product	4.6
Contact Center	2.9
Oil and Gas	1.6
Electronics	1.1
Marketing	0.3
Total Investments	100%

Rand Capital Corporation and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

Note 1. ORGANIZATION

Rand Capital Corporation (Rand, we, us and our) was incorporated under the laws of New York in February 1969. completed our initial public offering in 1971 as an internally managed, closed-end, diversified, management investment company. We have elected to be treated as a business development company (BDC) under the Investment Company Act of 1940, as amended (the 1940 Act). As a BDC, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in qualifying assets and provide managerial assistance to the portfolio companies in which we invest. See Item 1. Business Regulation, Regulation as a Business Development Company in our Annual Report on Form 10-K for the year ended December 31, 2017.

Throughout our history, our principal business has been to make venture capital investments in early or expansion stage companies, often in upstate New York and regions in close proximity. In accordance with our strategic growth plan, we look for companies with strong leadership that are bringing to market new or unique products, technologies or services and have a high potential for growth. We invest in a mixture of debt and equity instruments. The debt securities typically have an equity component in the form of warrants or options to acquire stock or the right to convert the debt securities into equity securities.

We established our first small business investment company (SBIC) in 2002, Rand Capital SBIC, Inc. (Rand SBIC), whereby we utilized funds borrowed from the Small Business Administration (SBA) combined with our capital to invest in our portfolio companies. We historically made the majority of our venture capital investments through Rand SBIC. Rand SBIC is predecessor was organized as a Delaware limited partnership and was converted into a New York corporation on December 31, 2008, at which time our operations as a licensed SBIC were continued. Although Rand SBIC was operated as if it were a BDC, it was registered as an investment company under the 1940 Act. In 2012, the SEC granted an Order of Exemption for Rand with respect to the operations of Rand SBIC, and then Rand SBIC filed an election to be regulated as a BDC under the 1940 Act. Rand SBIC is board of directors is comprised of the directors of Rand, a majority of whom are not interested persons of Rand or Rand SBIC.

During 2017 we established a second SBIC subsidiary, Rand Capital SBIC II, L.P. (Rand SBIC II), and began making investments through this SBIC subsidiary. During the first quarter of 2018, together with the SBA, we determined that the optimal structure was to revert back to investing in small businesses through our original SBIC, Rand SBIC, and the assets of Rand SBIC II were transferred to Rand SBIC. Rand SBIC has applied for \$6 million in new SBA leverage commitment and is currently undergoing the review and approval process.

We operate as an internally managed investment company whereby our officers and employees conduct the business of the Corporation under the general supervision of our Board of Directors. We have not elected to qualify to be taxed as a regulated investment company as defined under Subchapter M of the Internal Revenue Code.

In this Quarterly Report on Form 10-Q, unless the context otherwise requires, we the Corporation, us, and our reference Rand Capital Corporation and Rand SBIC.

Our corporate office is located in Buffalo, NY and our website address is www.randcapital.com. We make available free of charge on our website our annual and periodic reports, proxy statements and other information as soon as

reasonably practicable after such material is filed with the Securities and Exchange Commission (SEC). Our shares are traded on the NASDAQ Capital Market under the ticker symbol RAND .

21

Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation It is our opinion that the accompanying consolidated financial statements include all adjustments of a normal recurring nature necessary for a fair presentation in accordance with United States generally accepted accounting principles (GAAP) of the consolidated financial position, results of operations, cash flows and statement of changes in net assets for the interim periods presented. Certain information and note disclosures normally included in audited annual consolidated financial statements prepared in accordance with GAAP have been omitted; however, we believe that the disclosures made are adequate to make the information presented herein not misleading. Our interim results for the nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the full year.

These statements should be read in conjunction with the consolidated financial statements and the notes included in our Annual Report on Form 10-K for the year ended December 31, 2017. Information contained in this filing should also be reviewed in conjunction with our related filings with the SEC prior to the date of this report. Those filings include, but are not limited to, the following:

N-54A Election to Adopt Business Development Company status

DEF-14A 2018 Definitive Proxy Statement submitted to shareholders

Principles of Consolidation The consolidated financial statements include the accounts of Rand and its two wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Fair Value of Financial Instruments The carrying amounts reported in the consolidated statement of financial position of cash, interest receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term nature of these financial instruments.

Fair Value of SBA Debentures In September 2018, the SBIC Funding Corporation completed a pooling of SBA debentures that have a coupon rate of 3.548%, excluding a mandatory SBA annual charge estimated to be 0.804%, resulting in a total estimated fixed rate for ten years of 4.352%. The carrying value of Rand s SBA debentures is a reasonable estimate of fair value because their stated interest rates approximate current interest rates that are available for debt with similar terms.

In accordance with the provisions of the 1940 Act, the Corporation classifies its investments by level of control. Under the 1940 Act, Control Investments are investments in companies that the Corporation is deemed to Control because it owns more than 25% of the voting securities of the company or has greater than 50% representation on the company s board. Affiliate Investments are companies in which the Corporation owns between 5% and 25% of the voting securities. Non-Control/Non-Affiliate Investments are those companies that are neither Control Investments nor Affiliate Investments.

Investments Investments are valued at fair value as determined in good faith by the management of the Corporation and approved by the Board of Directors. The Corporation invests in loan instruments, debt instruments, and equity instruments. There is no single standard for determining fair value in good faith. As a result, determining fair value requires that judgment be applied to the specific facts and circumstances of each portfolio investment while employing a consistent valuation process. The Corporation analyzes and values each investment quarterly, and records unrealized depreciation for an investment that it believes has become impaired, including where collection of a loan or debt security or realization of the recorded value of an equity security is doubtful. Conversely, the Corporation will record unrealized appreciation if it believes that an underlying portfolio company has appreciated in value and,

therefore, its equity securities have also appreciated in value. These estimated fair values may differ from the values that would have been used had a ready market for the investments existed and these differences could be material if the Corporation s assumptions and judgments differ from results of actual liquidation events.

Qualifying Assets All of the Corporation s investments were made in privately held small business enterprises, that were not investment companies, were principally based in the United States, and represent qualifying assets as defined by Section 55(a) of the 1940 Act.

Cash and Cash Equivalents Temporary cash investments having a maturity of less than a year when purchased are considered to be cash equivalents.

Revenue Recognition Interest Income Interest income is recognized on the accrual basis except where the investment is in default or otherwise presumed to be in doubt. In such cases, interest is recognized at the time of receipt. A reserve for possible losses on interest receivable is maintained when appropriate.

Rand SBIC s interest accrual is also regulated by the SBA s Accounting Standards and Financial Reporting Requirements for Small Business Investment Companies. Under these rules, interest income cannot be recognized if collection is doubtful, and a 100% reserve must be established. The collection of interest is presumed to be in doubt when there is substantial doubt about a portfolio company s ability to continue as a going concern or a loan is in default for more than 120 days. Management also uses other qualitative and quantitative measures to determine the value of a portfolio investment and the collectability of any accrued interest.

The following investments are on non-accrual status: G-TEC Natural Gas Systems (G-Tec), First Wave Products Group, LLC (First Wave), OnCore Golf Technology, Inc. (Oncore) and a portion of the Mercantile Adjustment Bureau, LLC (Mercantile) outstanding loan balance.

The Corporation holds debt securities in its investment portfolio that contain payment-in-kind (PIK) interest provisions. PIK interest, computed at the contractual rate specified in each debt agreement, is periodically added to the principal balance of the debt and is recorded as interest income. Thus, the actual collection of this interest may be deferred until the time of debt principal repayment.

Revenue Recognition Dividend Income The Corporation may receive cash distributions from portfolio companies that are limited liability companies or corporations and these distributions are classified as dividend income on the consolidated statement of operations. Dividend income is recognized on an accrual basis when it can be reasonably estimated.

The Corporation may hold preferred equity securities that contain cumulative dividend provisions. Cumulative dividends are recorded as dividend income, if declared and deemed collectible, and any dividends in arrears are recognized into income and added to the balance of the preferred equity investment. The actual collection of these dividends in arrears may be deferred until such time as the preferred equity is redeemed.

Revenue Recognition Fee Income Consists of the revenue associated with the amortization of financing fees charged to the portfolio companies upon successful closing of SBIC financings and income associated with portfolio company board attendance fees. The income associated with the amortization of financing fees was \$28,266 and \$18,557 for the nine months ended September 30, 2018 and 2017, respectively. The board fees were \$2,000 and \$1,000 for the nine months ended September 30, 2018 and 2017, respectively. In addition, we recorded a fee of approximately \$142,000 for modifying a debt instrument during the nine months ended September 30, 2018.

Realized Gain or Loss and Unrealized Appreciation or Depreciation of Investments Amounts reported as realized gains and losses are measured by the difference between the proceeds from the sale or exchange and the cost basis of the investment without regard to unrealized gains or losses recorded in prior periods. The cost of securities that have, in management s judgment, become worthless are written off and reported as realized losses when appropriate.

Unrealized appreciation or depreciation reflects the difference between the fair value of the investments and the cost basis of the investments.

Original Issue Discount Investments may include original issue discount or OID income. This occurs when the Corporation purchases a warrant and a note from a portfolio company simultaneously, which requires an allocation of a portion of the purchase price to the warrant and reduces the note or debt instrument by an equal amount in the form of a note discount or OID. The note is reported net of the OID and the OID is accreted into interest income over the life of the loan. The Corporation recognized \$29,462 and \$21,085 in OID income for nine months ended September 30, 2018 and 2017, respectively. OID income is estimated to be approximately \$10,000 for the remainder of 2018.

Deferred Debenture Costs SBA debenture origination and commitment costs, which are netted against the debenture obligation (See Note 6 SBA Debentures), will be amortized ratably over the terms of the SBA debentures. Amortization expense was \$20,550 for each of the nine months ended September 30, 2018 and 2017. Amortization expense on currently outstanding debentures for the next five years is estimated to average approximately \$23,000 per year.

SBA Debentures The Corporation had \$8,000,000 in outstanding SBA debentures at September 30, 2018 and December 31, 2017 with a weighted average interest rate of 3.54%. The debentures are presented net of deferred debenture costs (See Note 6 SBA Debentures). The \$8,000,000 in outstanding SBA leverage matures from 2022 through 2025.

In the event of a future default of such SBA obligations, the Corporation has consented to the exercise, by the SBA, of all rights of the SBA under 13 C.F.R. 107.1810(i) SBA remedies for automatic events of default and has agreed to take all actions that the SBA may so require. These actions may include the Corporation s automatic consent to the appointment of the SBA, or its designee, as receiver under Section 311(c) of the Small Business Investment Act of 1958.

Net Assets per Share Net assets per share are based on the number of shares of common stock outstanding. The Corporation does not have any common stock equivalents outstanding.

Supplemental Cash Flow Information Income taxes (refunded) paid during the nine months ended September 30, 2018 and 2017 were (\$17,006) and \$590,940, respectively. Interest paid during each of the nine months ended September 30, 2018 and 2017 was \$282,875. The Corporation converted \$279,319 and \$262,105 of interest receivable into investments during the nine months ended September 30, 2018 and 2017, respectively.

Accounting Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Stockholders Equity (Net Assets) At September 30, 2018 and December 31, 2017, there were 500,000 shares of \$10.00 par value preferred stock authorized and unissued.

On October 25, 2018, the Board of Directors extended the repurchase authorization for up to 1,000,000 shares of the Corporation s outstanding common stock on the open market through October 25, 2019 at prices no greater than the then current net asset value. No shares were repurchased during the nine months ended September 30, 2018. At September 30, 2018, the total treasury shares held was 541,046 shares with a total cost of \$1,469,105.

Profit Sharing and Stock Option Plan In 2001, the stockholders of the Corporation authorized the establishment of an Employee Stock Option Plan (the Option Plan), that provides for the award of stock options to purchase up to

200,000 common shares to eligible employees. In 2002, the Corporation placed the Option Plan on inactive status as it developed a new profit sharing plan for the Corporation s employees in connection with the formation of its SBIC subsidiary. As of September 30, 2018, no stock options had been

awarded under the Option Plan. Because Section 57(n) of the 1940 Act prohibits maintenance of a profit sharing plan for the officers and employees of a BDC where any option, warrant or right is outstanding under an executive compensation plan, no stock options will be granted under the Option Plan while any profit sharing plan is in effect with respect to the Corporation.

In 2002, the Corporation established a Profit Sharing Plan (the Plan) for its executive officers in accordance with Section 57(n) of the 1940 Act. Under the Plan, the Corporation will pay its executive officers aggregate profit sharing payments equal to 12% of the net realized capital gains of its SBIC subsidiary, net of all realized capital losses and unrealized depreciation of the SBIC subsidiary, for the fiscal year, computed in accordance with the Plan and the Corporation s interpretation of the Plan. Any profit sharing paid or accrued cannot exceed 20% of the Corporation s net income, as defined in the Plan. For purposes of the 20% profit sharing test, the Corporation interprets net income to be the total of the Corporation s net investment gain (loss) and its net realized gain (loss) on investments, prior to inclusion of the estimated profit sharing obligation. The profit sharing payments are split equally between the Corporation s two executive officers, each of whom is fully vested in the Plan.

The Corporation did not record any expense pursuant to the Plan for the nine months ended September 30, 2018 and 2017, respectively. Included in the profit sharing and bonus payable line on the Consolidated Statement of Financial Position at December 31, 2017 was \$132,000 that was paid during the first quarter of 2018.

Income Taxes The Corporation reviews the tax positions it has taken to determine if they meet a more likely than not threshold for the benefit of the tax position to be recognized in the consolidated financial statements. A tax position that fails to meet the more likely than not recognition threshold will result in either a reduction of a current or deferred tax asset or receivable, or the recording of a current or deferred tax liability. There were no uncertain tax positions recorded at September 30, 2018.

It is the Corporation s policy to include interest and penalties related to income tax liabilities in income tax expense. There were no amounts recognized for interest or penalties for the nine months ended September 30, 2018 or 2017.

Concentration of Credit and Market Risk The Corporation's financial instruments potentially subject it to concentrations of credit risk. Cash is invested with banks in amounts which, at times, exceed insurable limits. Management does not anticipate non-performance by such banks.

The following are the concentrations of the top five portfolio company values to the fair value of the Corporation s total investment portfolio:

	September 30, 2018	December 31, 2017
Genicon, Inc. (Genicon)	13%	12%
eHealth Global Technologies, Inc. (eHealth),	11%	11%
Rheonix, Inc. (Rheonix)	9%	9%
Tilson Technology Management, Inc. (Tilson)	8%	8%
Outmatch (Outmatch)	7%	7%

Note 3. INVESTMENTS

The Corporation s investments are carried at fair value in accordance with Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures , which defines fair value, establishes a framework for measuring fair

value in GAAP, and expands disclosures about fair value measurements.

25

Loan investments are defined as traditional loan financings with no equity features. Debt investments are defined as debt financings that include one or more equity features such as conversion rights, stock purchase warrants, and/or stock purchase options. A financing may also be categorized as a debt financing if it is accompanied by the direct purchase of an equity interest in the company.

The Corporation uses several approaches to determine the fair value of an investment. The main approaches are:

Loan and debt securities are valued at cost when it is representative of the fair value of the investment or sufficient assets or liquidation proceeds are expected to exist from a sale of a portfolio company at its estimated fair value. However, they may be valued at an amount other than cost given the carrying interest rate versus the related inherent portfolio risk of the investment. A loan or debt instrument may be reduced in value if it is judged to be of poor quality, collection is in doubt or insufficient liquidation proceeds exist.

Equity securities may be valued using the asset approach, market approach or income approach. The asset approach involves estimating the liquidation value of the portfolio company is assets. To the extent the value exceeds the remaining principal amount of the debt or loan securities of the portfolio company, the fair value of such securities is generally estimated to be their cost. However, where value is less than the remaining principal amount of the loan and debt securities, the Corporation may discount the value of an equity security. The market approach uses observable prices and other relevant information generated by similar market transactions. It may include the use of market multiples derived from a set of comparables to assist in pricing the investment. Additionally, the Corporation adjusts valuations if a subsequent significant equity financing has occurred that includes a meaningful portion of the financing by a sophisticated, unrelated new investor. The income approach employs a cash flow and discounting methodology to value an investment.

ASC 820 classifies the inputs used to measure fair value into the following hierarchy:

Level 1: Quoted prices in active markets for identical assets or liabilities, used in the Corporation s valuation at the measurement date. Under the valuation policy, the Corporation values unrestricted publicly traded companies, categorized as Level 1 investments, at the average closing bid price for the last three trading days of the reporting period.

Level 2: Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or other observable inputs other than quoted prices.

Level 3: Unobservable and significant inputs to determining the fair value.

Financial assets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Any changes in estimated fair value are recorded in the statement of operations.

There were no Level 1 or 2 investments as of September 30, 2018.

In the valuation process, the Corporation values restricted securities, categorized as Level 3 investments, using information from these portfolio companies, which may include:

Audited and unaudited statements of operations, balance sheets and operating budgets;

Current and projected financial, operational and technological developments of the portfolio company;

Current and projected ability of the portfolio company to service its debt obligations;

26

The current capital structure of the business and the seniority of the various classes of equity if a deemed liquidation event were to occur;

Pending debt or capital restructuring of the portfolio company;

Current information regarding any offers to purchase the investment, or recent fundraising transactions;

Current ability of the portfolio company to raise additional financing if needed;

Changes in the economic environment which may have a material impact on the operating results of the portfolio company;

Internal circumstances and events that may have an impact (both positive and negative) on the operating performance of the portfolio company;

Qualitative assessment of key management;

Contractual rights, obligations or restrictions associated with the investment; and

Other factors deemed relevant by the Corporation s management to assess valuation. The valuation may be reduced if a portfolio company s performance and potential have deteriorated significantly. If the factors that led to a reduction in valuation are overcome, the valuation may be readjusted.

Equity Securities

Equity securities may include preferred stock, common stock, warrants and limited liability company membership interests.

The significant unobservable inputs used in the fair value measurement of the Corporation s equity investments are earnings before interest, tax and depreciation and amortization (EBITDA) and revenue multiples, where applicable, the financial and operational performance of the business, and the debt and senior equity preferences that may exist in a deemed liquidation event. Standard industry multiples may be used when available; however, the Corporation s portfolio companies are typically small and in early stages of development and these industry standards may be adjusted to more closely match the specific financial and operational performance of the portfolio company. Due to the nature of certain investments, fair value measurements may be based on other criteria, which may include third party appraisals. Significant changes in any of these unobservable inputs may result in a significantly higher or lower fair value estimate.

Another key factor used in valuing equity investments is a significant recent arms-length equity transaction entered into by the portfolio company with a sophisticated, non-strategic, unrelated, new investor. The terms of these equity

transactions may not be identical to the equity transactions between the portfolio company and the Corporation, and the impact of the difference in transaction terms on the market value of the portfolio company may be difficult or impossible to quantify.

When appropriate the Black-Scholes pricing model is used to estimate the fair value of warrants for accounting purposes. This model requires the use of highly subjective inputs including expected volatility and expected life, in addition to variables for the valuation of minority equity positions in small private and early stage companies. Significant changes in any of these unobservable inputs may result in a significantly higher or lower fair value estimate.

For recent investments of less than one year old, the Corporation generally relies on the cost basis, which is deemed to represent the fair value, unless other fair value inputs are identified causing the Corporation to depart from this basis.

27

Loan and Debt Securities

The significant unobservable inputs used in the fair value measurement of the Corporation s loan and debt securities are the financial and operational performance of the portfolio company, similar debt with similar terms with other portfolio companies, as well as the market acceptance for the portfolio company s products or services. These inputs will likely provide an indicator as to the probability of principal recovery of the investment. The Corporation s loan and debt investments are often junior secured or unsecured debt securities. Fair value may also be determined based on other criteria where appropriate. Significant changes to the unobservable inputs may result in a change in fair value. For recent investments, the Corporation generally relies on the cost basis, which is deemed to represent the fair value, unless other fair value inputs are identified causing the Corporation to depart from this basis.

The following table provides a summary of the significant unobservable inputs used to determine the fair value of the Corporation s Level 3 portfolio investments as of September 30, 2018:

Investment Type		Market Approach EBITDA Multiple	L	Market Approach iquidation Seniority		Market Approach Revenue Multiple		Market Approach Transaction Pricing		Totals
Non-Control/Non-Affiliate Equity	\$		\$	25	¢	2,645,496	¢	6,209,950	•	8,855,471
Non-Control/Non-Affiliate Debt	\$	949,040	Ψ	1,739,639	Ψ	3,500,000	Ψ	300,000	Ψ	6,488,679
Total	Φ	0.40, 0.40	Φ	1 720 ((4	Φ	C 1 4 5 40 C	Φ	< 500 050	ф	15 244 150
Non-Control/Non-Affiliate	\$	949,040	\$	1,739,664	Þ	6,145,496	>	6,509,950)	15,344,150
Affiliate Equity	\$	4,420,000	\$	22,841	\$	4,053,430	\$	1,031,477	\$	9,527,748
Affiliate Debt		5,935,859						1,265,000		7,200,859
Total Affiliate	\$	10,355,859	\$	22,841	\$	4,053,430	\$	2,296,477	\$	16,728,607
Control Equity	\$		\$		\$	99,500	\$		\$	99,500
Total Control	\$		\$		\$	99,500	\$		\$	99,500
Total Level 3 Investments	\$	11,304,899	\$	1,762,505	\$	10,298,426	\$	8,806,427	\$	32,172,257
Range Unobservable Input	F	4X-9X EBITDA Multiple	A	1X Asset Value	F	1X-3.3X Revenue Multiple		Not Applicable Transaction Price		
Weighted Average		5.6X	-	1X	•	2.1X		Not Applicable		

The following table provides a summary of the components of Level 1, 2 and 3 Assets Measured at Fair Value at September 30, 2018:

Fair Value Measurements at Reported Date Using

Quoted Prices in Active Markets for

		Identical			Other Significant		
	Cantamban	Assets	O	Uı	nobservable		
Description	September 2018	30, (Lever 1)	Observable Inputs (Level 2)		Inputs (Level 3)		
Loan investments	\$ 4,325,0	000 \$	\$	\$	4,325,000		
Debt investments	9,364,5	38			9,364,538		
Equity investments	18,482,7	'19			18,482,719		
Total	\$ 32,172,2	257 \$	\$	\$	32,172,257		

The following table provides a summary of the components of Level 1, 2 and 3 Assets Measured at Fair Value on a Recurring Basis at December 31, 2017:

Fair Value Measurements at Reported Date Using Quoted Prices in Active Markets for

Fair Value Measurements Using Significant

		Identical			Other Significant		
		Assets Significant		Unobservable			
	December 31,	(Level	Observable Inputs		Inputs		
Description	2017	1)	(Level 2)		(Level 3)		
Loan investments	\$ 3,550,000	\$	\$	\$	3,550,000		
Debt investments	10,096,244				10,096,244		
Equity investments	18,637,818				18,637,818		
Total	\$ 32,284,062	\$	\$	\$	32,284,062		

The following table provides a summary of changes in Assets Measured at Fair Value Using Significant Unobservable Inputs (Level 3) for the nine months ended September 30, 2018:

		Unobservable Inputs (Level 3) Venture Capital Investments				
	Loan	Debt				
Description	Investments	Investments	Investments	Total		
Ending Balance, December 31, 2017, of						
Level 3 Assets	\$3,550,000	\$ 10,096,244	\$ 18,637,818	\$ 32,284,062		
Realized loss included in net change in						
net assets from operations:						
Intrinsiq Material, Inc. (Intrinsiq)			(1,125,673)	(1,125,673)		
Total Realized Losses			(1,125,673)	(1,125,673)		
Unrealized Losses included in net						
change in net assets from operations:						
Empire Genomics, LLC (Empire						
Genomics)		(901,360)		(901,360)		
First Wave Products Group, LLC (First						
Wave)		(250,000)		(250,000)		
GiveGab, Inc. (Givegab)			191,907	191,907		
Intrinsiq			725,673	725,673		
SOMS Technologies, LLC (SOMS)			(498,348)	(498,348)		
,			, ,	, ,		
Total Unrealized Losses		(1,151,360)	419,232	(732,128)		

Table of Contents 69

<u>Purchases of Securities/Changes to Securities/Non-cash conversions:</u>

Edgar Filing: RAND CAPITAL CORP - Form 10-Q

BeetNPath, LLC (Beetnpath)		140,000		140,000
Centivo Corporation (Centivo)			201,342	201,342
Empire Genomics		274,106		274,106
Genicon, Inc. (Genicon)		153,548		153,548
GoNoodle, Inc. (GoNoodle)		7,739		7,739
KnowledgeVision Systems, Inc.				
(Knowledgevision)	775,000			775,000
Microcision LLC (Microcision)		14,392		14,392
SciAps, Inc. (Sciaps)			250,000	250,000
Total Purchases of Securities/Changes				
to Securities/Non-cash conversions	775,000	589,785	451,342	1,816,127
Repayments and Sale of Securities:				
Empire Genomics		(21,665)		(21,665)
Knoa Software, Inc. (Knoa)		(48,466)		(48,466)
Total Repayments and Sale of Securities		(70,131)		(70,131)
Transfers within Level 3		(100,000)	100,000	
Ending Balance, September 30, 2018,				
of Level 3 Assets	\$4,325,000	\$ 9,364,538	\$ 18,482,719	\$ 32,172,257
Change in unrealized depreciation on inve	stments for the	period included i	n changes in	
net assets				(\$ 732,128)
Net realized loss on investments for the pe	riod included in	n changes in		
net assets				(\$ 1,125,673)

The following table provides a summary of changes in Assets Measured at Fair Value Using Significant Unobservable Inputs (Level 3) for the nine months ended September 30, 2017:

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Venture Capital Investments Loan Debt Equity				
Description	Investments	Investments	Investments	Total	
Ending Balance, December 31, 2016,					
of Level 3 Assets	\$ 3,200,000	\$ 6,700,221	\$ 17,600,260	\$ 27,500,481	
Unrealized Gains and Losses included in net change in net assets from operations:					
ACV Auctions, Inc. (ACV Auctions)			119,356	119,356	
Athenex, Inc. (Athenex)			308,336	308,336	
BeetNPath, LLC (Beetnpath)			29,723	29,723	
City Dining Cards, Inc. (Loupe)			(500,000)	(500,000)	
Mercantile Adjustment Bureau, LLC			(= = = , = = = ,	(= = = , = =)	
(Mercantile)		(250,000)		(250,000)	
SciAps, Inc. (Sciaps)			(300,000)	(300,000)	
Teleservices Solutions Holdings, LLC			, , ,	, ,	
(Teleservices)			(395,398)	(395,398)	
Total Unrealized Gains and Losses Purchases of Securities/Changes to		(250,000)	(737,983)	(987,983)	
Securities/Non-cash conversions:		100,000	11 277	111,277	
Beetnpath Centivo Corporation (Centivo)		100,000	11,277	100,000	
eHealth Global Technologies, Inc.		100,000		100,000	
(eHealth)	2,000,000			2,000,000	
Empire Genomics, LLC (Empire	2,000,000			2,000,000	
Genomics)		201,489		201,489	
Genicon, Inc. (Genicon)	300,000	893,588	120,000	1,313,588	
GoNoodle, Inc. (GoNoodle)	300,000	7,662	120,000	7,662	
KnowledgeVision Systems, Inc.		7,002		7,002	
(Knowledge Vision)	50,000			50,000	
Mercantile	30,000	107,497		107,497	
Microcision LLC (Microcision)		17,403		17,403	
Sciaps		17,105	274,274	274,274	
o timpo			271,277	271,277	
Total Purchases of Securities/Changes					
to Securities/Non-cash conversions	2,350,000	1,427,639	405,551	4,183,190	
Transfers within Level 3	(2,000,000)	1,450,000	550,000		
Transfers out of Level 3	(=,000,000)		(725,000)	(725,000)	
			(. ==,000)	(. =2,000)	

Ending Balance, September 30, 2017,							
of Level 3 Assets	\$ 3,550,000	\$ 9,327,860	\$ 17,092,828	\$ 2	9,970,688		
Change in unrealized depreciation on inv	estments for the	period included i	n changes in				
net assets				(\$	987,983)		
Net realized gain on investments for the period included in changes in							
net assets				\$			

NOTE 4. OTHER ASSETS

At September 30, 2018 and December 31, 2017, other assets was comprised of the following:

	Septem	ber 30, 2018	Decem	ber 31, 2017
Prepaid expenses	\$	34,621	\$	
Operating receivables		2,899		3,204
Equipment (net)		840		2,490
Dividend receivable				37,160
Total other assets	\$	38,360	\$	42,854

Note 5. COMMITMENTS AND CONTINGENCIES

The Corporation had one commitment to fund a \$50,000 investment at September 30, 2018.

Note 6. SBA DEBENTURES

Pursuant to Accounting Standard Update (ASU) 2015-03, the debt origination costs associated with the SBA debt obligations are presented as a direct deduction of the related debt obligation.

	Septe	mber 30, 2018	Decei	mber 31, 2017
Debentures guaranteed by the SBA	\$	8,000,000	\$	8,000,000
Less unamortized issue costs		(124,277)		(144,827)
Debentures guaranteed by the SBA, net	\$	7,875,723	\$	7,855,173

31

Note 7. FINANCIAL HIGHLIGHTS

The following schedule provides the financial highlights, calculated based on weighted average shares outstanding, for the nine months ended September 30, 2018 and 2017:

	Nine months ended September 30, 2018 (Unaudited)		Septe	months ended mber 30, 2017 Jnaudited)
Income from investment operations (1):				
Investment income	\$	0.23	\$	0.17
Operating expenses		0.24		0.25
Investment loss before income taxes		(0.01)		(0.08)
Income tax benefit		0.00		(0.03)
income tax benefit		0.00		(0.03)
Net investment loss		(0.01)		(0.05)
Net realized and unrealized loss on				
investments		(0.20)		(0.10)
		, ,		, ,
Decrease in net asset value		(0.21)		(0.15)
Net asset value, beginning of period		5.05		5.16
Net asset value, end of period	\$	4.84	\$	5.01
Per share market price, end of period	\$	2.40	\$	2.96
Tel share market price, end of period	Ψ	2.40	Ψ	2.90
Total return based on market value		(20.5%)		(6.3%)
Total return based on net asset value		(4.2%)		(2.9%)
Supplemental data:				,
Ratio of operating expenses before				
income taxes to average net assets		4.8%		4.9%
Ratio of operating expenses				
including income taxes to average				
net assets		2.9%		3.2%
Ratio of net investment loss to				
average net assets		(0.2%)		(0.9%)
Portfolio turnover		4.2%		13.4%
Net assets, end of period	\$	30,587,676	\$	31,692,476
Weighted shares outstanding, end of				
period		6,321,988		6,321,988

⁽¹⁾ Per share data are based on weighted average shares outstanding and the results are rounded to the nearest cent.

The Corporation s interim period results could fluctuate as a result of a number of factors; therefore results for any interim period should not be relied upon as being indicative of performance for the full year or in future periods.

Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the consolidated financial statements and related notes included elsewhere in this report. Historical results and percentage relationships among any amounts in the consolidated financial statements are not necessarily indicative of trends in operating results for any future periods.

FORWARD LOOKING STATEMENTS

Statements included in this Management s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report that do not relate to present or historical conditions are forward-looking statements within the meaning of that term in Section 27A of the Securities Act of 1933, as amended, and in Section 21E of the Securities Exchange Act of 1934, as amended. Additional oral or written forward-looking statements may be made by us from time to time, and forward-looking statements may be included in documents that are filed with the Securities and Exchange Commission. Forward-looking statements involve risks and uncertainties that could cause our results or outcomes to differ materially from those expressed in the forward-looking statements. Forward-looking statements may include, without limitation, statements relating to our plans, strategies, objectives, expectations and intentions and are intended to be made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as believes, forecasts, intends, possible, expects, estimates, anticipates, or plans and simila are intended to identify forward-looking statements. Among the important factors on which such statements are based are assumptions concerning the state of the United States economy and the local markets in which our portfolio companies operate, the state of the securities markets in which the securities of our portfolio companies could be traded, liquidity within the United States financial markets, and inflation. Forward-looking statements are also subject to the risks and uncertainties described under the caption Risk Factors contained in Part II, Item 1A of this report and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017.

There may be other factors not identified that affect the accuracy of our forward-looking statements. Further, any forward-looking statement speaks only as of the date when it is made and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time that may cause our business not to develop as we expect, and we cannot predict all of them.

Overview

We are an internally managed investment company that lends to and invests in small companies often concurrently with other investors. We have elected to be treated as a business development company (BDC) under the Investment Company Act of 1940, as amended (the 1940 Act). As a BDC, we are required to comply with certain regulatory requirements. We have historically made the majority of our investments through our wholly-owned subsidiary, Rand Capital SBIC, Inc. (Rand SBIC), which operates as a small business investment company (SBIC) and has been licensed by the U.S. Small Business Administration (SBA) since 2002. During 2017 we established a second SBIC subsidiary, Rand Capital SBIC II, L.P. (Rand SBIC II) and began making investments through this SBIC subsidiary. During the first quarter of 2018, together with the SBA, we determined that the optimal structure was to revert back to investing in small businesses through our original SBIC, Rand SBIC, and the assets of Rand SBIC II were transferred to Rand SBIC. Rand SBIC has applied for an additional \$6 million in new SBA leverage commitments and is currently undergoing the review and approval process.

Outlook

At the end of the third quarter of 2018, we had approximately \$4.4 million in cash and cash equivalents available for future investments and expenses. We believe the combination of cash and cash equivalents on hand, proceeds from portfolio exits, anticipated additional SBA leverage, and prospective investment income provide sufficient capital for us to continue to add new investments to our portfolio while reinvesting in existing portfolio companies that demonstrate continued growth potential. The following short and long-term trends provide us confidence in our ability to grow Rand:

We expect that well run businesses will require capital to grow and should be able to compete effectively given the strong macroeconomic environment and eager reception of new technologies and service concepts.

We continue to manage risk by investing with other investors, when possible.

We are actively involved with the governance and management of our portfolio companies, which enables us to support their operating and marketing efforts and facilitate their growth.

We have sufficient cash to invest in new opportunities and to opportunistically repurchase shares. At the end of the third quarter of 2018, we had authorization to repurchase an additional 458,954 shares of our common stock. However, our prioritized use of cash continues to be growing our portfolio.

When our portfolio expands, we are able to better leverage our infrastructure.

Critical Accounting Policies

We prepare our consolidated financial statements in accordance with United States generally accepted accounting principles (GAAP), which require the use of estimates and assumptions that affect the reported amounts of assets and liabilities. A summary of our critical accounting policies can be found in our Annual Report on Form 10-K for the year ended December 31, 2017 under Item 7 Management s Discussion and Analysis of Financial Condition and Results of Operations.

34

Financial Condition

	Septe	mber 30, 2018	Dece	Decrease	% Decrease	
Overview:						
Total assets	\$	38,658,226	\$	40,133,913	(\$1,475,687)	(3.7%)
Total liabilities		8,070,550		8,215,228	(144,678)	(1.8%)
Net assets	\$	30,587,676	\$	31,918,685	(\$ 1,331,009)	(4.2%)

Net asset value per share (NAV) was \$4.84 at September 30, 2018 and \$5.05 at December 31, 2017.

Our gross outstanding SBA debentures at September 30, 2018 were \$8,000,000 and will mature from 2022 through 2025. Cash and cash equivalents approximated 14% of net assets at September 30, 2018, as compared to 20% at December 31, 2017.

Composition of Our Investment Portfolio

Our financial condition is dependent on the success of our portfolio holdings. We have invested substantially all of our assets in small to medium-sized companies. The following summarizes our investment portfolio at the dates indicated.

	Sente	ember 30, 2018	Dece	ember 31. 2017	Increase (Decrease)	% Increase (Decrease)
Investments, at cost	¢	37,309,642	\$	36,689,319	\$ 620,323	1.7%
•	Ψ	, ,	Ψ	, ,		
Unrealized depreciation, net		(5,137,385)		(4,405,257)	(732,128)	16.6%
Investments at fair value	\$	32,172,257	\$	32,284,062	(\$ 111,805)	(0.3%)

Our total investments at fair value, as estimated by management and approved by our Board of Directors, approximated 105% of net assets at September 30, 2018 versus 101% of net assets at December 31, 2017.

The change in investments during the nine months ended September 30, 2018, at cost, is comprised of the following:

	Cost		
	Increase (Decrease		
New investments:			
KnowledgeVision Systems, Inc. (Knowledgevision)	\$	775,000	
SciAps, Inc. (Sciaps)		250,000	
Centivo Corporation (Centivo)		200,000	
BeetNPath, LLC (Beetnpath)		140,000	
Total of new investments		1,365,000	
Other changes to investments:			

Edgar Filing: RAND CAPITAL CORP - Form 10-Q

Empire Genomics, LLC (Empire Genomics)	
capitalized fee income and interest conversion	274,106
Genicon Inc. (Genicon) interest conversion and	
OID amortization	153,548
Microcision LLC (Microcision) interest conversion	14,392
GoNoodle, Inc. (GoNoodle) interest conversion	7,740
Centivo interest conversion	1,342
Total of other changes to investments	451,128
Investments repaid, sold or liquidated:	
Intrinsiq Material, Inc. (Intrinsiq) realized loss	(1,125,673)
Knoa Software Inc. (Knoa) repayment	(48,466)
Empire Genomics repayment	(21,666)
Total of investments repaid, sold or liquidated	(1,195,808)
•	
Net change in investments, at cost	\$ 620,323

Results of Operations

Our principal investment objective is to achieve long-term capital appreciation on our equity investments while maintaining a current cash flow from our debt instruments and pass-through equity instruments to fund expenses. Therefore, we invest in a variety of financial instruments to provide a current return on a portion of the investment portfolio.

Comparison of the three months ended September 30, 2018 to the three months ended September 30, 2017

Investment Income

	Three months ended September 30, 20188		 ree months ended nber 30, 2017	Increase	% Increase
Interest from portfolio companies	\$	450,289	\$ 309,922	\$ 140,367	45.3%
Interest from other investments		7,872	6,348	1,524	24.0%
Dividend and other investment					
income		48,856	76,813	(27,957)	(36.4%)
Fee income		155,285	3,936	151,349	3,845.2%
Total investment income	\$	662,302	\$ 397,019	\$ 265,283	66.8%

The total investment income that is received on a current basis for the three months ended September 30, 2018 is received from ten portfolio companies. This contrasts with the nine portfolio companies generating current income for the three months ended September 30, 2017.

Interest from portfolio companies Interest from portfolio companies was approximately 45% higher during the three months ended September 30, 2018 versus the same period in 2017 due to the fact that we have originated more income-producing debt investments in the last year. The new debt instruments were originated from Genicon Inc. (Genicon), eHealth Global Technologies, Inc. (eHealth) and several other portfolio companies. In addition, during the third quarter of 2018 the Empire Genomics loans were modified and resulted in a recording of interest that had previously not been accrued of approximately \$91,000. This amount was capitalized into the loan balance as part of the debt modification and is non-recurring.

The following investments are on non-accrual status: G-TEC Natural Gas Systems (G-Tec), First Wave Products Group, LLC (First Wave), OnCore Golf Technology, Inc. (Oncore) and a portion of the Mercantile Adjustment Bureau, LLC (Mercantile) outstanding loan balances.

<u>Interest from other investments</u> The increase in interest from other investments is primarily due to higher interest rates during the three months ended September 30, 2018 versus the same period in 2017.

<u>Dividend and other investment income</u> Dividend income is comprised of cash distributions from limited liability companies (LLCs) and corporations in which we have invested. Our investment agreements with certain LLCs require those LLCs to distribute funds to us for payment of income taxes on our allocable share of the LLC s profits. These portfolio companies may also elect to make additional discretionary distributions. Dividend income will fluctuate based upon the profitability of these LLCs and corporations and the timing of the distributions or the impact of new

investments or divestitures. The dividend distributions for the respective periods were:

	Sept	nonths ended ember 30, 2018	Three months ende September 30, 2017		
Carolina Skiff LLC (Carolina Skiff)	\$	39,169	\$	41,999	
Tilson Technology Management, Inc.					
(Tilson)		9,687		5,000	
New Monarch Machine Tool, Inc.					
(New Monarch)				27,409	
Empire Genomics LLC (Empire					
Genomics)				2,405	
Total dividend and other investment income	\$	48,856	\$	76,813	

<u>Fee income</u> Fee income consists of the revenue associated with the amortization of financing fees charged to the portfolio companies upon successful closing of SBIC financings and income from portfolio company board attendance fees. The financing fees are amortized ratably over the life of the instrument associated with the fees. The unamortized fees are carried on the balance sheet under the line item Deferred revenue.

The income associated with the amortization of financing fees was \$12,939 and \$3,936 for the three months ended September 30, 2018 and 2017, respectively.

In addition, we recorded a one-time debt modification fee of approximately \$142,000 during the three month ended September 30, 2018. We charged the fee to Empire Genomics and the fee was capitalized into the Empire Genomics loan balances as part of the debt modification.

The portion of total investment income that is received in cash, on a current basis, is received from nine portfolio companies.

Expenses

	Three months ended Three months ended					
	Sept	September 30, 2018		tember 30,		
				2017	Increase	% Increase
Total expenses	\$	447,800	\$	439,048	\$ 8,752	2.0%

Expenses predominately consist of interest expense on outstanding SBA borrowings, compensation expense, and general and administrative expenses, including stockholder and office operating expenses and professional fees.

The increase in expenses during the three months ended September 30, 2018 versus the same period in 2017 was primarily caused by a 69%, or \$33,312, increase in professional fees. Professional fees are higher during the third quarter of 2018 because we continue to incur expenses in connection with developing and implementing our long-term growth strategy. These expenses included external legal, tax consulting and other advisory expenses to support refinement of our strategy, which involved assessing options relative to the complex regulatory environment in which we operate.

This increase was offset by a \$26,299 recovery of bad debt expense associated with the Empire Genomics loan modification for the three months ended September 30, 2018. There was no bad debt expense (recovery) for the three months ended September 30, 2017.

Realized Losses on Investments

	Three	ł			
	Sep	otember 30, 2018	September 30, 2017	Change	
Realized loss on investments				_	
before income taxes	(\$	1.125.673)	\$	(\$ 1.125.673)	

During the three months ended September 30, 2018, we recognized a loss on our investment in Intrinsiq Material, Inc. (Intrinsiq) when the company was sold and we did not receive any proceeds. There were no realized gains or losses

during the three months ended September 30, 2017.

37

Change in Unrealized Depreciation of Investments

	Three	months ended	Three	months ended	
	September 30, 2018		September 30, 2017		Change
Change in unrealized depreciation					J
of investments before income taxes	\$	475,802	\$	111,000	\$ 364,802

The change in unrealized depreciation, before income taxes, for the three months ended September 30, 2018 was comprised of the following:

	Three months ended September 30, 2018	
Empire Genomics, LLC (Empire Genomics) Intrinsiq Material, Inc. (Intrinsiq) realized loss	(\$	249,871) 725,673
Total change in net unrealized depreciation of investments before income taxes during the three months ended September 30, 2018	\$	475,802

The valuation of our investment in Empire Genomics was decreased after we reviewed the portfolio company s operations and current and projected financial condition, after the debt modification, and determined that a valuation adjustment was necessary.

Intrinsiq was sold during the third quarter of 2018 and a realized loss was recorded.

The change in unrealized depreciation, before income taxes, for the three months ended September 30, 2017 was comprised of the following:

	Three months ended September 30, 2017	
Athenex, Inc. (Athenex)	\$	111,000
Total change in net unrealized depreciation of investments before income taxes during the three months ended September 30, 2017	\$	111,000

Athenex completed an initial public offering (IPO) during the second quarter of 2017 and its shares of common stock are now publicly traded on the NASDAQ Global Select Market under the symbol ATNX. At September 30, 2017 we held 46,296 shares of the common stock of Athenex and valued these shares using the average bid price for the last three trading days of the reporting period, which was then discounted 10% due to restrictions on the sale of the shares.

Subsequent to quarter end, the sale restrictions on our shares in Athenex common stock were removed and these shares became freely tradable.

All of these value adjustments resulted from a review by our management using the guidance set forth by ASC 820 and our established valuation policy.

Net (Decrease) Increase in Net Assets from Operations

We account for our operations under GAAP for investment companies. The principal measure of our financial performance is net (decrease) increase in net assets from operations on our consolidated statements of operations. For the three months ended September 30, 2018 and 2017, the net (decrease) increase in net assets from operations was (\$179,302) and \$57,931, respectively.

38

Comparison of the nine months ended September 30, 2018 to the nine months ended September 30, 2017

Investment Income

Nine months ended Nine months ended						
	Se	ptember 30,	Sep	otember 30,	Increase	% Increase
		2018		2017	(Decrease)	(Decrease)
Interest from portfolio companies	\$	1,063,337	\$	833,653	\$ 229,684	27.6%
Interest from other investments		20,717		24,182	(3,465)	(14.3%)
Dividend and other investment						
income		181,963		197,403	(15,440)	(7.8%)
Fee income		172,612		19,557	153,055	782.6%
Total investment income	\$	1,438,629	\$	1,074,795	\$ 363,834	33.9%

The total investment income that is received on a current basis for the nine months ended September 30, 2018 is received from ten portfolio companies. This contrasts with the nine portfolio companies generating current income for the nine months ended September 30, 2017.

Interest from portfolio companies Interest from portfolio companies was approximately 28% higher during the nine months ended September 30, 2018 versus the same period in 2017 due to the fact that we have originated more income-producing debt investments in the last year. These new debt instruments were originated from Genicon Inc. (Genicon), eHealth Global Technologies, Inc. and several other portfolio companies. In addition, during the third quarter of 2018 the Empire Genomics loans were modified and resulted in a recording of interest that had previously not been accrued of approximately \$91,000. This amount was capitalized into the loan balance as part of the debt modification.

The following investments are on non-accrual status: G-TEC Natural Gas Systems (G-Tec), First Wave Products Group, LLC (First Wave), OnCore Golf Technology, Inc. (Oncore) and a portion of the Mercantile Adjustment Bureau, LLC (Mercantile) outstanding loan balance.

<u>Interest from other investments</u> The decrease in interest from other investments is primarily due to lower average cash balances during the nine months ended September 30, 2018 versus the same period in 2017.

<u>Dividend and other investment income</u> The dividend distributions for the respective periods were:

	Nine months ended September 30, 2018		Nine months ended September 30, 2017	
Carolina Skiff LLC (Carolina Skiff)	\$	119,433	\$	141,372
Tilson Technology Management, Inc.				
(Tilson)		29,063		15,000
New Monarch Machine Tool, Inc. (New				
Monarch)		27,409		27,409
		6,058		7,598

Empire Genomics LLC (Empire
Genomics)
SOMS Technologies, LLC (SOMS)

6,024

Total dividend and other investment

<u>Fee income</u> The income associated with the amortization of financing fees was \$28,266 and \$18,557 for the nine months ended September 30, 2018 and 2017, respectively. The income from board fees was \$2,000 and \$1,000 for the nine months ended September 30, 2018 and 2017, respectively.

\$

181,963

\$

197,403

In addition, we recorded a one-time debt modification fee of approximately \$142,000 during the nine month ended September 30, 2018. We charged the fee to Empire Genomics and the fee was capitalized into the Empire Genomics loan balances as part of the debt modification.

Expenses

income

	Nine r	nonths ended	Nine	months ended		
	Septer	nber 30, 2018	Septe	mber 30, 2017	Decrease	% Decrease
Total expenses	\$	1,510,034	\$	1,562,620	(\$ 52,586)	(3.4%)

39

The decrease in expenses during the nine months ended September 30, 2018 is due to an overall decrease of 29%, or \$89,855, in professional fees as compared to the same period in 2017. This decrease was offset by a \$50,342 charge to bad debt expense for the nine months ended September 30, 2018 while there was no bad debt expense for the nine months ended September 30, 2017.

Realized Losses on Investments

			Nine months ended September 30, 2017	Change
Realized loss on investments	-	,	,	Š
before income taxes	(\$	1.125.673)	\$	(\$1,125,673)

During the nine months ended September 30, 2018, we recognized a loss on our investment in Intrinsiq Material, Inc. (Intrinsiq) when the company was sold and we did not receive any proceeds.

Change in Unrealized Depreciation of Investments

		onths ended			Cl
	Septem	ber 30, 2018	Septen	1ber 30, 2017	Change
Change in unrealized					
depreciation of investments					
before income taxes	(\$	732,128)	(\$	987,983)	(\$ 255,855)

The change in unrealized depreciation, before income taxes, for the nine months ended September 30, 2018 was comprised of the following:

		nonths ended nber 30, 2018
Empire Genomics, LLC (Empire Genomics)	(\$	901,360)
SOMS Technologies, LLC (SOMS)		(498,348)
First Wave Products Group (First Wave)		(250,000)
GiveGab, Inc. (Givegab)		191,907
Intrinsiq Material, Inc. (Intrinsiq) realized loss		725,673
Total change in net unrealized depreciation of investments before income taxes during the nine months ended September 30, 2018	(\$	732,128)

The valuations of our investments in Empire Genomics and SOMS were decreased after we reviewed each of the portfolio company s operations and current and projected financial condition and determined that a valuation adjustment was necessary.

Our valuation of First Wave was decreased to reflect an anticipated round of financing expected to be completed by First Wave in the fourth quarter of 2018.

Givegab s value was increased to the cost basis of the investment after a financial analysis of the portfolio company indicating continued improved performance. Intrinsiq was sold during the third quarter of 2018 and a realized loss was recorded.

The change in unrealized depreciation, before income taxes, for the nine months ended September 30, 2017 was comprised of the following:

		nonths ended aber 30, 2017
City Dining Cards, Inc. (Loupe)	(\$	500,000)
Teleservices Solutions Holdings, LLC		
(Teleservices)		(395,398)
SciAps, Inc. (Sciaps)		(300,000)
Mercantile Adjustment Bureau, LLC (Mercantile)		(250,000)
Athenex, Inc. (Athenex)		308,336
ACV Auctions, Inc. (ACV)		119,356
BeetNPath, LLC (Beetnpath)		29,723
Total change in net unrealized depreciation of investments before income taxes during the nine months ended September 30, 2017	(\$	987,983)

40

The valuations of our investments in Loupe, Mercantile and Teleservices were decreased after we reviewed each portfolio company and its current and projected financial condition and determined that a valuation adjustment was necessary.

The valuation of Sciaps was decreased to revalue our equity holdings based upon the liquidation preferences of our securities as compared to the most recent equity round of financing completed by Sciaps.

In accordance with our valuation policy, we increased the value of our investments in ACV and Beetnpath based on a significant equity financing by a new non-strategic outside entity.

Athenex completed an initial public offering (IPO) during the second quarter of 2017 and its shares of common stock were publicly traded on the NASDAQ Global Select Market under the symbol ATNX. At September 30 2017 we held 46,296 shares of the common stock of Athenex and valued the shares using the average bid price for the last three trading days of the reporting period, which was then discounted due to restrictions on the sale of the shares.

All of these value adjustments resulted from a review by our management using the guidance set forth by ASC 820 and our established valuation policy.

Net Decrease in Net Assets from Operations

We account for our operations under GAAP for investment companies. The principal measure of our financial performance is net decrease in net assets from operations on our consolidated statements of operations. For the nine months ended September 30, 2018 and 2017, the net decrease in net assets from operations was (\$1,331,009) and (\$936,887), respectively.

Liquidity and Capital Resources

Our principal long-term objective is to achieve growth in net asset value per share through capital appreciation. Therefore, a significant portion of our investment portfolio is structured to maximize the potential for capital appreciation, and certain portfolio investments may be structured to provide little or no current yield in the form of dividends or interest payments.

As of September 30, 2018, our total liquidity consisted of approximately \$4.4 million in cash and cash equivalents on hand.

Net cash used by operating activities has averaged approximately \$626,000 over the last three years. The average cash used for investment in portfolio companies over the last three years was approximately \$3,700,000. Our cash flow from operations may fluctuate based on the timing of the receipt of dividend income and realized gains and the associated income taxes paid. We will generally use cash to fund our operating expenses and also to invest in companies, as we seek to build our portfolio utilizing our available cash and proceeds from liquidations of portfolio investments. We anticipate that we will continue to exit investments. However, the timing of liquidation events within the portfolio is difficult to project with any certainty. As of September 30, 2018, we did not have any outstanding commitments to borrow funds from the SBA. Starting in 2022, our SBA debt begins to reach maturity, and this will require us to identify sources of future funding if liquidation of investments is not sufficient to fund operations and repay the SBA debt obligation.

41

We believe that the cash on hand at September 30, 2018, the scheduled interest payments on our portfolio investments and the anticipated additional SBA leverage will be sufficient to meet our cash needs for the next twelve months. We continue to seek potential exits from portfolio companies to increase the amount of liquidity available for new investments, operating activities and future SBA debenture repayment obligations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our investment activities contain elements of risk. Our investment portfolio consists of equity and debt securities in private companies and is subject to valuation risk. Because there is typically no public market for the equity and debt securities in which we invest, the valuation of the equity interests in the portfolio is stated at fair value as determined in good faith by our management and approved by our Board of Directors. This is in accordance with our investment valuation policy (see the discussion of valuation policy contained in Note 3. Investments in the consolidated financial statements contained in Item 1 of this report, which is hereby incorporated herein by reference.) In the absence of readily ascertainable market values, the estimated value of the portfolio may differ significantly from the values that would be placed on the portfolio if a ready market for the investments existed. Any changes in valuation are recorded on the consolidated statement of operations as Net change in unrealized depreciation on investments.

At times, a portion of our portfolio may include marketable securities traded in the over-the-counter market. In addition, there may be a portion of the portfolio for which no regular trading market exists. In order to realize the full value of a security, the market must trade in an orderly fashion or a willing purchaser must be available when a sale is to be made. Should an economic or other event occur that would not allow markets to trade in an orderly fashion, we may not be able to realize the fair value of our marketable investments or other investments in a timely manner.

As of September 30, 2018 we did not have any off-balance sheet arrangements or hedging or similar derivative financial instrument investments.

Item 4. Controls and Procedures

Disclosure Controls and Procedures. The Corporation maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC s rules and forms, and that this information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. The Chief Executive Officer and the Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of the Corporation s disclosure controls and procedures as September 30, 2018. Based on the evaluation of these disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded that the Corporation s controls and procedures were effective as of September 30, 2018.

Changes in Internal Control over Financial Reporting. There have been no changes in our internal control over financial reporting during the Corporation s most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Corporation s internal control over financial reporting.

PART II.

OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

See Part I, Item 1A, Risk Factors, of the Annual Report on Form 10-K for the year ended December 31, 2017.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

			To	tal number of sha	ares
				purchased	Maximum number of
				as part of	shares that may yet be
		Total number of Av	verage price paid	publicly	purchased under the share
		shares purchased	per share	announced	repurchase
Period		(1)	(2)	plan (3)	program
7/1/2018	7/31/2018				458,954
8/1/2018	8/31/18				458,954
9/1/2018	9/30/2018				458,954

- (1) There were no shares repurchased during the third quarter of 2018.
- (2) The average price paid per share is calculated on a settlement basis and includes commission.
- (3) On October 25, 2018, the Board of Directors extended the repurchase authorization of up to 1,000,000 shares of the Corporation s common stock on the open market at prices no greater than the then current net asset value through October 25, 2019.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

43

Item 6. Exhibits

(a)	Exhibits
	The following exhibits are filed with this report or are incorporated herein by reference to a prior filing, in accordance with Rule 12b-32 under the Securities Exchange Act of 1934.
(3.1)(i)	Certificate of Incorporation of the Corporation, incorporated by reference to Exhibit (a)(1) of Form N-2 filed with the Securities Exchange Commission on April 22, 1997. (File No. 333-25617).
(3.1)(ii)	By-laws of the Corporation, incorporated by reference to Exhibit 3(ii) to the Corporation s Quarterly Report on Form 10-Q for the period ended September 30, 2016 filed with the Securities Exchange Commission on November 2, 2016. (File No. 814-00235).
(4)	Specimen certificate of common stock certificate, incorporated by reference to Exhibit (b) of Form N-2 filed with the Securities Exchange Commission on April 22, 1997. (File No. 333-25617).
(31.1)	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended filed herewith.
(31.2)	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended filed herewith.
(32.1)	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Rand Capital Corporation filed herewith.

44

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 7, 2018

RAND CAPITAL CORPORATION

By: /s/ Allen F. Grum Allen F. Grum, President

By: /s/ Daniel P. Penberthy
Daniel P. Penberthy, Treasurer

45